PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page [ADDRESS_365656] UDY  PROTOC OL 
 
Protocol #X31025  
A Phase 1 Evaluation of the Safety and Tolerab ility of TAK-228 in  Combination with 
TAK-117 an d Paclitaxel in Advanced Solid Tumors 
 
 
 
 
 
 
 
Indication: Advanced solid tumo rs 
 
Phase:  
1 
 
 
 
 
Protocol His tory 
Original                                                 March 6 , 2017 
      Amendment 1                                       March  26, 2018 
   Amendment 2 May 1, 2019  
   Amendment 3     January  24, 2020  
 
 
 
 
Investigator and Study Center:  
Casey Williams, Pharm.D., BCOP  
Avera Cancer Institute  
[ADDRESS_365657] 
Sioux Falls, S D [ZIP_CODE] 
(605) 322- [ADDRESS_365658]. Casey Williams , (who may 
also be referred to as the sponsor -investigator), is conduc ting the study and actin g as the sponsor . 
Therefore, the l egal/ethical obligations  of the pr incipal investigator include both those  of a 
sponsor  and those  of an inve stigator. 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 2 
X31025 Protocol Version  4 24-January- 2020  PROTOC OL SUMMA RY 
 
 
Study Title: A Phase 1 Evaluation of the Safety and Tolerability of TAK-228 in Combination with 
TAK-117 and Pa clitaxel in Advanced So lid Tumors 
 
Phase: 1 
 
Number of Patients: 2-30 
 
Study O bjectives 
 
Primary 
 
• To determine the maximum tolerated dose of the combination of  TAK -228, TAK -117 and 
paclitaxel for the treatment of patients with adv anced solid tumors 
 
Seconda ry 
 
• To determine the objective response rate (according to RECI ST 1.1 r esponse criteri a) 
Tertiary/Exploratory 
• To describe symptom occu rrence and severity and Health Related Quality of Life (HRQOL)  
as measured by [CONTACT_299707] -LASA respec tively 
 
• To assess whether patients with specific alterations respond m ore favorably to the combination 
 
Overview of Study D esign: 
 
Phase 1 trial. 3 + 3 design to determine  the safety and tolerability of the combin ation of TAK -
228, TAK -117 and paclitaxel in patients w ith advanced solid  tumo rs. The maximum tol erable dose 
(MTD)  will be assessed, whi ch is the dose level at which less than one-third of patients will experience 
a dose  limiting  toxicity. 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 3 
X31025 Protocol Version  4 24-January- 2020   
 
Study Popul ation: The study popul ation w ill consist of patients with adv anced  solid tumors. 
 
Inclusion Criteria: 
 
• Male or female patients 1 8 years or older 
• Patients must h ave a diagnosis of  an advanced solid tumor  malignancy and must be refractory 
to or intolerant of existing  therapi[INVESTIGATOR_299659] a clinical benefit  
• Eastern Cooperative Oncology Group (ECOG) performance status and/or other performance 
status of 0 -2 
• Female patients who:  
o Are postm enopa usal for at least [ADDRESS_365659] and agree 
to practice one effective method of pregnancy prevention contraception a nd one  
addition al effective (barrier) method, a t the same tim e, from the time of si gning the 
informed consent through 90 days (or longer as mandated by [CONTACT_231932] [e.g., 
USPI, SmPC, etc.,]) after the last dose of study drug, OR  
o Agree to prac tice true abstin ence, when this is in line  with the  preferred and usua l 
lifestyle of t he patient. (Periodic abstin ence [e.g., calendar, ovul ation, s ympto - thermal 
and post ovul ation m ethods ], withd rawal, spe rmicides onl y, and lactational amenorrhea 
are not  acceptable methods  of contraception. F emale and m ale condoms should not be  
used tog ether.) 
• Male patients, even if surgically sterilized (i.e., status post -vasectomy), who:  
o Agree to practice highly effective barrier contraception  during the entire study 
treatment period a nd thr ough [ADDRESS_365660] dose  of study drug, OR 
o Agree to prac tice true abstinence, when this is in line with the  preferred and usua l 
lifestyle of t he patient. (Periodic abstin ence [e.g., calendar, ovu lation, s ympto - thermal 
and post  ovulation methods  for the fe male partner], withd rawal, spermicides only, and 
lactational amenorrh ea are not  acceptable methods of contraception. Fe male and male 
condoms should not be  used tog ether.) 
o Agree not to dona te sperm during the course of this study or within  [ADDRESS_365661] dose  of study drug 
• Screening clinical laboratory values as specified below:  
o Bone marrow reserve consistent with: absolute neutrophil count (ANC) ≥1.5 x 109/L; 
platelet count ≥100 x 109/L; hemoglobin ≥9 g/dL without transfusion within 1- week 
preceding study drug administration  
o Hepatic: total bi lirubin ≤1.5 x upper limit of normal (ULN), transaminases (aspartate 
aminotransferase/serum glutamic oxaloacetic transaminase-  AST/SGOT and alanine 
aminotransferase/serum glutamic pyruvic transaminase -ALT/SGPT) ≤2.[ADDRESS_365662] (≤[ADDRESS_365663] if liver metastases are present)  
o Renal: creatinine c learance ≥50 mL/min b ased either on C ockcroft-Gault estimate or 
based on ur ine collection (12 or  24 ho ur) 
o Metabolic: Glycosylated hemoglobin (HbA1 c) <7.0%, fasting  serum glucose (≤ 130 
mg/dL) and fasting triglycerides ≤300 m g/dL 
• Ability to swallow oral medications  
• Voluntary written consent must be given before performance of any study related procedure not 
part of standard medical care, with the understanding that the patient may withdraw consent at 
any time without prejudice to future medical care  
• Patients who have a history of brain metastasis are eligible for the study provided that all the 
following criteria are met:  
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page [ADDRESS_365664] been treated  
o No evidence of disease progression  for ≥[ADDRESS_365665] dose  of 
TAK -228 
o No ong oing requirement for dexamethasone or anti-epi[INVESTIGATOR_299660] C riteria: 
 
• Active central nervous system (CNS) metastasis  
• Other clinically significant co -morbidities, in the opi[INVESTIGATOR_7372], such as 
uncontrolled pulmonary disease, active central nervous system disease, active infection, or any 
other condition that could compromise the pati ent’s participation in the study  
• Known human immunodeficiency virus infection  
• Known hepatitis B surface antigen -positive, or known or suspected active hepatitis C infection.  
• Any serious medical or psychiatric illness that could, in the investigator’s opi[INVESTIGATOR_21677], potentially 
interfere with the completion of treatment according to this protocol  
• Diagnosed or treated for another malignancy within [ADDRESS_365666] undergone complete resection . 
• Breast feeding or pregnant  
• Treatment with any investigational products within [ADDRESS_365667] dose of study drug  
• Previous treatment with PI3K, AKT, dual PI3K/mTOR inhibitors, TORC1/2 inhibitors (prior 
treatment with everolimus is allowed)  
• Manifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI disease, or for an  
unknown reason that may alter the absorption of TAK -228. In addition, patients with small 
bowel or jejunal  stomata are also excluded . 
 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 5 
X31025 Protocol Version  4 24-January- 2020   
• History of any of the following within the last [ADDRESS_365668] dose 
of the drug:  
o Ischemic myocardial event, including angina requiring therapy and artery 
revascularization procedures 
o Ischemic  cerebrovascular  event, including transient  ischemic attack  and artery 
revascularization procedures 
o Requirement for  inotropic  support  (exclu ding digoxin)  or serious (uncontrolled) cardiac 
arrhythmia (including atrial flutter/fibrillation, ventricular fibrillation or ventricular 
tachycardia)  
o Placement of a pacemaker for control of rhythm  
o [LOCATION_001] Heart Association (NHYA) Class III or IV heart f ailure (See Appendix B)  
o Pulmonary embolism  
• Significant ac tive cardiova scular or pulmonar y disease including: 
o Uncontrolled hyp ertension (i.e., systolic blood pre ssure >180 mm H g, diastolic blood 
pressure >95 mm Hg ). Use of a nti-hyper tensive ag ents to c ontrol hyp ertension befo re 
Cycle1 Day 1 is allowed. 
o Pulmon ary hype rtension  
o Uncontrolled asthma or O2 s aturation <90% by a rterial blood ga s analysis or pulse  
oxim etry on r oom a ir 
o Signi ficant va lvular disease; severe regurgit ation or st enosis by [CONTACT_299708] c ontrol with m edical intervention, or history of va lve replacement 
o Medically signi ficant (symptom atic) bradycardia 
o History of arr hythmia  requi ring an impl antable c ardiac defibrillator 
o Baseline p rolong ation of the ra te-corrected QT int erval (QTc) (e.g., repeated 
demonst ration of QTc int erval >[ADDRESS_365669] ome, or torsades de point es) 
• Poorly controlled diabetes mellitus defined as glycosylated hemoglobin (HbA1c)  >7%; patients 
with a history of transien t glucose intolerance due to corticosteroid administration may be 
enrolled in this study if all other inclusion/exclusion criteria are met 
• Treatment with strong inhibitors and/or inducers of cytochrome P450 (CYP) 3A4, CYP2C19 or 
CYP2C19 within [ADDRESS_365670] dose of study drug 
• Patients receiving systemic corticosteroids (either IV or oral steroids, excluding inhalers or 
low-dose hormone replacement therapy  – doses of prednisone <  10mg or equivalent are 
allowed ) within [ADDRESS_365671] dose of study drug  
• Daily or chronic use of a proton pump inhibitor (PPI) and/or having taken a PPI  [INVESTIGATOR_874] [ADDRESS_365672] dose of study drug  
 
Duration of Study: Patients will complete [ADDRESS_365673] stable disease or better after 3 cycles can continue therapy 
until progression. 
 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 6 
X31025 Protocol Version  4 24-January- 2020  TABLE OF CONTENTS 
 
STUDY OVE RVIEW DIAGR AM (optional ) ....................................................................... NA 
LIST OF TABLES AND  FIGUR ES (OPTIONAL)  .............................................................. NA 
TABLES ................................................................................................................................. NA 
FIGURES ............................................................................................................................... NA 
LIST OF ABBREVIATIONS AND G LOSSARY OF TER MS  .............................................. 9 
1. INTRODUC TION  .............................................................................................................. 12 
1.1 Dis ease Under Treatment .............................................................................................. 12 
1.2 S tudy Drugs ................................................................................................................... 13 
1.2.1 TAK -228  ................................................................................................................ 13 
1.2.2 TAK -117  ................................................................................................................ 13 
2. SUMMA RY OF  NON CLINICAL EXPERIENCE ............................................................ 14 
2.1 TAK -228........................................................................................................................ 14 
2.1.1 TAK -228 in C ombina tion with P aclita xel  .............................................................. 15 
2.2 Nonc linical E xperience with TAK117   .......................................................................... 16 
2.3 TAK -228 in C ombina tion with TAK -117 ( PI[INVESTIGATOR_299658] ) ................................................... 16 
3. SUMMA RY OF  CLINICAL EXPERIENCE  .................................................................... 17 
3.1 C linical E xperience with TAK- 228  ............................................................................... 17 
3.2 C linical E xperience with TAK- 117  ............................................................................... 19 
3.3 C linical E xperience with TAK- 228 +  TAK-117 (PI[INVESTIGATOR_299658]; study C32001)  ................ 21 
3.3.1 P harmacokine tics  .................................................................................................... 21 
3.3.2 P harmacod ynamics  ................................................................................................. 21 
3.3.3 S afety ...................................................................................................................... 22 
3.3.4 P otential Risks  ........................................................................................................ 22 
4. SPE CIAL WARNINGS AND PR ECAUTIONS  ............................................................... 23 
4.1 Insulin a nd Gl ucose Levels ............................................................................................ 23 
4.2 C ardiac Effects  .............................................................................................................. 24 
4.3 R enal Function............................................................................................................... 24 
4.4 R ash ............................................................................................................................... 25 
4.5 P neumonitis   ................................................................................................................... 25 
4.6 Interactions   ................................................................................................................... 25 
5. RATIONA LE FOR THE RP 2D F OR PI[INVESTIGATOR_299658]  (TAK- 228 + TAK- 117)  .......................... 25 
6. STUDY R ATIONALE  ....................................................................................................... 26 
Treatme nt-Related Symptom C hecklis t ............................................................................... 28 
Potential Biomarkers  ........................................................................................................... 28 
7. STUDY O BJECTIVES  ...................................................................................................... 28 
7.1 P rimary Objectiv es  ........................................................................................................ 28 
7.2 S econda ry Objectiv es  .................................................................................................... 28 
7.3 T ertiary/Explora tory Objectiv es (if appli cable)  ............................................................ 29 
8. STUDY ENDP OINTS   ........................................................................................................ 29 
8.1 P rimary Endpoints   ......................................................................................................... 29 
8.2 S econda ry Endpoints  ..................................................................................................... 29 
8.3 T ertiary/Explora tory Endpoints ( if appli cable)  ............................................................. 29 
9. STUDY DE SIGN  ............................................................................................................... 29 
9.1 Over view of Study Design  ............................................................................................ 29 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 7 
X31025 Protocol Version  4 24-January- 2020  9.2 S creeni ng Procedures/Enrollme nt  ................................................................................. [ADDRESS_365674] UG ................................................................................................................. 43 
11.1 S tudy Drug Admin istration  ......................................................................................... 43 
11.2 D efinitions of  Dose-Limiting  Toxicity (Ph1 studies onl y .................................... 44 
11.3 Dos e-Modi fication  Guid elines  .................................................................................... 45 
11.3.1 C riteria for Dose Interruption dur ing a  Cycle ...................................................... 46 
11.3.2 C riteria for Discontinua tion of  Study Drugs  ........................................................ 46 
11.3.3 R ecomm ended Dose Modi fications f or Paclitaxel Treatme nt Asso ciated 
Toxicity  ................................................................................................................ 46 
12. E XCLUD ED CONC OMI TANT M EDICATIONS A ND PR OCEDURE S . .................... 46 
12.1 P ermitte d Concomitant M edications a nd Procedures (if appli cable)  .......................... 48 
12.2 P recautions a nd R estrictions  ...................................................................................... 48 
12.3 M anagement of Clinical Ev ents (if appli cable)  ......................................................... 50 
12.3.1 M anagement of Hyperglycemia  ........................................................................... 52 
12.3.2 M anagement of Hyperlipi[INVESTIGATOR_035]  ........................................................................... 53 
12.3.3 M anagement of Oral Mu cositis   ............................................................................ 54 
12.3.4 M anagement of Rash  ............................................................................................ 55 
12.3.5 M anagement of Nausea/Vomiting   ........................................................................ 56 
12.3.6 M anagement of Cardiac Abnormalities  ................................................................ 57 
12.3.7 M anagement of Patients with QTc  Prolong ation ................................................. 58 
12.3.8 M anagement of Asthenia, Weakne ss and Fatigue  ................................................ 59 
12.3.9 M anagement of Asparte Aminotransferase/Alanine Aminot ransferase 
Elevations   ............................................................................................................. 60 
12.3.10 M anagement of Non-infectious P neumonitis   ..................................................... 61 
12.4 D escription of  Investigational Agents  ......................................................................... 61 
12.5 P reparation, R econs titution, a nd Dispe nsing   ............................................................. 62 
12.6 P ackaging and Labeling  .............................................................................................. 62 
12.7 S torage, Handling, and A ccount ability  ....................................................................... 63 
12.8 S tudy Compli ance  ....................................................................................................... 64 
12.9 T ermination of  Treatment and/or  Study Participation  ............................................... 64 
13. Dose Expansion ................................................................................................................. 64 
14. S TATISTICAL AND QUANT ITATIVE ANAL YSES  .................................................. 64 
14.1 S tatistical M ethods   ...................................................................................................... 64 
15. ADVE RSE EVENT S  ....................................................................................................... 65 
15.1 D efinitions   ................................................................................................................... 65 
15.1.1 Adver se Event Definition   ..................................................................................... 65 
15.1.2 Adver se Drug Reaction  ....................................................................................... 65 
15.1.3 S erious Adver se Event Definition   ........................................................................ 66 
15.2 P rocedure s for Reporting Serious Adv erse Events  ..................................................... 67 
15.3 P rocedure s for Reporting Drug Exposur e During Pregnancy and Birth Events  ......... 69 
16. ADM INISTRATIVE REQUIREMENTS   ........................................................................ 69 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page [ADDRESS_365675] aints  ..................................................................................................... 69 
17. R EFERENCES  ................................................................................................................. 71 
Appendix 1: E astern Cooperative  Oncology Group (ECOG) Scale  for Perf ormance  
Status ............................................................................................................... 75 
Appendix 2: Cockcroft-Gault Equa tion ............................................................................... 76 
Appendix 3: New Yo rk Heart Association C lassification of  Cardiac Disease .................... 77 
Appendix 4: List of  Relevant Cytochrome P450 Inhibitor s and Inducers ........................... 78 
Appendix 5: Guide lines for TAK- 228/117 and Paclita xel Dose  Modi fication a nd Delay.. 79 
Appendix 6: Health  Related  Quality  of Life Assessment ………………………………….82 
Appendix 7: Therapy  Related  Symptoms  Checklist ……………………………………….83 
 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page [ADDRESS_365676] OF ABBREVIAT IONS  AND GLOSSARY OF  TER MS 
 
Abbre viation Term 
AE adverse event 
AKT Protein kinase B 
ALP/ SGPT alkaline phosphatase 
ALT alanine aminotransferase 
ANC absolute neutrophil count 
API [INVESTIGATOR_299661]/ SGOT  aspartate aminotransferase 
BCRP  breast cancer resistance protein  
BID bis in die; twice a day 
CBC complete blood count 
CL clear ance, IV dosing 
CNS central nervous system 
CO2 carbo n dioxide 
CR complete response 
CRM  continual reassessment method 
CV cardiovascular 
DLT dose-limiting toxicity 
DNA deoxyribonucl eic acid 
EC ethics committee 
ECG elect rocardiogram; elect rocardiography 
ECHO echocardiogram 
ECOG Eastern Coope rative Oncology Group 
eCRF elect ronic case report form 
EOS End of Study (visit) 
EOT End of Treatment (visit) 
EU European Union 
FDA [LOCATION_002] Food and Drug Administration 
FSG Fasting serum glucose 
GCP Good Clinical Practice  
GI Gastrointestinal 
GLP Good Laboratory Practices  
GMP  Good Manufacturing Practice 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page [ADDRESS_365677] Hematocrit  
HDP E high-density polyethylene 
hERG human ether-à-go-go related  gene 
HIV human immu nodeficiency virus 
Hy’s Law Drugs that conform to Hy’s Law have a high potential for severe liver injury 
IB Investigator’s Brochure 
IC50 concentration producing 50% inhibition 
ICF informed consent form 
IEC independent ethics committee 
IRB institutional review board 
IV intravenous; intravenously 
IVRS interactive voice respons e system 
Ki inhibition constant 
LDH lactate  dehydrogenase 
LFT liver function test(s) 
LLN Lower limit normal 
LVEF Left ventricular ejection fraction 
MedDRA Medical Dicti onary for Regulatory Activities 
MM multiple myeloma 
MOA mechanism of action 
MRI magnetic resonance imaging 
MTD maximum tolerated dose 
mTOR mechanistic target of rapamycin 
mTOR[1] or [2] target of rapamycin complex [1 or 2] 
MUGA multiple gated acquisition (scan) 
NCCN Natio nal Comprehensive Cancer Network 
NCI Natio nal Cancer Institute 
NCI CTCAE Natio nal Cancer Institute Common Terminology Criteria for Adverse Events 
NHL  non-Hodgkin lymphoma 
NPO nothing by [CONTACT_299709] A [LOCATION_001] Heart Association 
PD progressive disease (disease progression) 
PK pharmacokinetic(s) 
PGx Pharmacogenomic(s)  
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 11 
X31025 Protocol Version  4 24-January- 2020  Abbre viation Term 
PO 
 per os; by [CONTACT_1966] (oral ly) 
PPI [INVESTIGATOR_299662] e choos e one 
PRO patient-reported outcome 
PSA prostate-specific antigen 
QD quaq ue die; each day; once daily 
QID quater  in die; 4 times a day 
QOD  quaq ue altera die; every other day 
QOL  quality of life 
QTc rate-corrected  QT interval (millisecond) of elect rocardiograph 
RBC red blood cell 
RECIST Respons e Evaluation Criteria in Solid Tumors 
RP2D Recomme nded phase 2 dose 
SAE serious adverse event 
SC Subcutaneous 
SD stable disease 
TGI tumor growth inhibition 
Tmax single-dose time to reach maximum (peak) concentration 
TIA Transient ischemic attack 
TPN Total parental nutrition 
[LOCATION_006] [LOCATION_008] 
ULN upper limit of the normal range 
US [LOCATION_002] 
Vz volume of distribution in the terminal phase 
WBC  white blood cell 
WM Waldenström macroglobunemia 
 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 12 
X31025 Protocol Version  4 24-January- 2020  1. INTRODUCTION 
1.1 Disease Under Treatment  
The treatment of patients with advanced solid tumors remains unsatisfactory. New combinations 
are needed to improve the outcomes for patients with advanced disease. Thus, successful 
treatment of advanced solid tumors represents a great challenge. The optimal combination, 
sequencing of treatment, and schedule for targeted drugs and chemotherapy has not been 
established. Little is also kn own regarding the unique molecular characteristics and  patterns  of 
each individual’s  cancer  tumor  cells.  New  pathway -driven molecular  subtypes are just now 
being elucidated1 and clinical trials with molecularly targeted therapy,  for example, in the 
differe nt types of advanced solid tumors are urgently needed using theragnostic information2, 3. 
 
Therapi[INVESTIGATOR_299663]. These novel therapi[INVESTIGATOR_299664]. Previously, factors used to make traditional  
chemotherapy  decisions  were based  on the tissue  of origin or histological subtype. But now, in 
the era of precision medicine, therapeutic strategies must be based on the degree of addiction of 
an individual tumor to the pathway being targeted. Identifying the oncogenic drivers of solid 
tumors and having drugs that target these drivers and/or pathways are the keys to the successful 
treatment of cancer in the future.  
 
There were approximately 14.1 million new cases of cancer globally in 2012 (not including skin 
cancer other than melanoma), which resulted in nearl y 8.[ADDRESS_365678] al, lung and cervical4. The addition of skin cancer, other than 
melanoma, would account for around 40% of cases in the total number of new cancers each 
year6, 7. The financial costs of cancer are also staggering and have been estimated at $1.[ADDRESS_365679] common cancer 
(and the 18th most common cancer overall) worldwide. Approximately 239,000 cases were  
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 13 
X31025 Protocol Version  4 24-January- 2020  recorded in 2012, accounting for nea rly 4% of all new cases of cancer in women (2% overall). 
This cancer is usually fatal, and is the eighth most common cause of cancer death in women 
worldwide (14th overall)8. Cancers of the ovary, fallopi[INVESTIGATOR_8916], and peritoneal origin exhibit 
similar behav iors and clinical and molecular characteristics. As such, these are often combined 
together and define epi[INVESTIGATOR_76296] (EOC). About  85–90% of ovarian cancers are 
epi[INVESTIGATOR_299665].  
1.2 Study Drugs  
1.2.1 TAK -228 
Millennium has developed TAK -228 (formerly INK128 and MLN0128), a novel, highly 
selective, orally bioavailable adenosine 5’ triphosphate (ATP) -competitive inhibitor of the 
serine/threonine kinase referred to as the mechanistic target of rapamycin (mTOR). TAK -[ADDRESS_365680] mTOR complexes, TORC1 and TORC2. 
 
In oncology, TAK -228 is being investigated as a treatment for advanced solid tumors and 
hematologic malignancies, either as monotherapy or in combination with chemotherapy, other 
molecularly targeted therapi[INVESTIGATOR_014], or antih ormonal agents. 
1.2.2 TAK -117 
TAK- 117 (formerly MLN1117/INK1117) is an investigational, orally (PO) available, selective 
small molecule inhibitor of the Class I phosphoinositide 3- kinase (PI3K) alpha isoform (PI3Kα).  
 
Pharmacological data obtained to date suggest that TAK -[ADDRESS_365681], lung, endometrial, colon, gastroesophageal, 
gastric, and bladder cancers, among others.  
 
TAK- 117 is being developed for the treatment of advanced solid tumors, both as a single agent 
and in combination with chemotherapy, such as paclitaxel and docetaxel, or other targeted 
therapi[INVESTIGATOR_299666]8237 (alisertib) and TAK -659. 
 
TAK- 117 is also being investigated in combination with the investigational agent TAK -228. 
  
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 14 
X31025 Protocol Version  4 24-January- 2020  2. SUMMARY OF NONCLINICAL EXPERIENCE  
2.1 TAK -228 
The mammalian mTOR serine/threonine kinase has a central role in regulating cellular growth 
and metabolism in response to external environmental factors9, 10. The mTOR kinase binds with 
other proteins to form two distinct multiprotein complexes, TORC1 and TORC2. The TORC1 
complex is stimulated by [CONTACT_299710] S6 kinase (S6K) and eukaryotic initiation factor 
4-binding protein (4E -BP1)11. The TORC2 complex is activated by [CONTACT_299711], proliferation, and actin cytoskeleton organization by [CONTACT_299712], such as serine/threonine- specific protein kinase (AKT) kinase (also known 
as protein kinase B), which is a regulator of apoptosis12, 13. 
 
Two major classes of mTOR inhibitors are under development, allosteric inhibitors and ATP -
competitive inhibitors. The first- generation, or allosteric, inhibitors include rapamycin and the  
related  analogs  or rapalogs  temsirolimus,  everolimus  and ridaforolimus.  The rapalogs 
effectively inhibit phosphoryla tion of S6K but only partially inhibit the phosphorylation of 4E -
BP1, which regulates cap -dependent translation of transcripts for cell survival, proliferation and 
angiogenesis10. Thus, rapamycin and the rapalogs are only partial inhibitors of TORC110. 
 
The ATP -competitive inhibitors, such as TAK -228, bind to the catalytic domain of mTOR and 
thus inhibit both TORC1 and TORC2 complexes, including the rapamycin- insensitive or 
resistant actions of TORC1, such as phosphorylation of 4E -BP114-16. 
 
The rapalogs, t emsirolimus and everolimus, have been approved by [CONTACT_48354] (FDA) as monotherapy for patients with advanced renal cell carcinoma 
(temsirolimus and everolimus), advanced pancreatic neuroendocrine tumors (everolimus), and 
subependym al giant cell astrocytoma associated with tuberous sclerosis (everolimus). However, 
resistance to single -agent rapalog therapy occurs and may be related to either incomplete 
inhibition of the targeted pathway or loss of S6K -mediated feedback inhibition of growth factor 
receptor signaling leading to paradoxical hyperactive signaling. The normal feedback loop 
involves activated S6K, which phosphorylates and inactivates insulin receptor  substrate -1 and 
inhibits  signaling  through the PI3K  pathway17, 18. In the presence of  rapalogs, the feedback loop 
is abrogated, leading to continued PI3K signaling, TORC2 activation, and subsequent 
phosphorylation of AKT at threonine -308 and serine -473, which markedly enhances the activity 
of AKT10, 13, 19, 20. 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page [ADDRESS_365682] demonstrated that TAK -228 selectively and potently inhibits the mTOR 
kinases with an IC50 of 1.1 nM. Relative to mTOR inhibition, TAK -228 has >100- fold less 
potency on class I (PI3K isoforms α, β, γ, δ), class II (PI3KC2α and PI3K2Cβ) and class III 
(VPS34) PI3K family members as well as PI4Kα and PI4Kβ.  
 
TAK- 228, administered orally in multiple human tumor xenograft mouse models, can inhibit 
angiogenesis and tumor growth by [CONTACT_299713] a dose - and time -dependent manner. These 
effects display a clear pharmacokinetic (PK) -to-pharmacodynamic relationship21. TAK- 228 
inhibits both the phosphorylation of S6 and 4E -BP1, the downstream substrates of TORC1, and 
selectively inh ibits AKT phosphorylation at serine -473 (S473), as evidenced by [CONTACT_299714], the downstream substrate of TORC218, 21, 22. Dual TORC1/[ADDRESS_365683] a number of human solid tumor cell -line xenograft mouse models, including 
phosphatase and tensin homolog (PTEN) mutant endometrial, breast and renal cell  carcinomas.  
 
For detailed information regarding the nonclinical pharmacology and toxicology of TAK -228 
please refer to the Investigator’s Brochure (IB).  
2.1.[ADDRESS_365684] of paclitaxel26. Therefore, TAK -228 should be given after paclitaxel 
administration in order not to interfere with th e mechanism of paclitaxel.  
  
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 16 
X31025 Protocol Version  4 24-January- 2020  2.2 Nonclinical Experience with TAK117  
Activating som atic missense mutations  (e.g., E542K, E545K  and H1047R ) in the 
phospha tidylinositol- 4, 5-bisphospha te 3 -kinase, catalytic subunit  alpha (PIK3CA) gene 
encoding the p110α  catalytic subunit  of PI3Kα have been identified as a major mechanism f or 
PI3K-dependent malignant transformation, pr oliferation and survival. PIK3CA mut ations ha ve 
been reported to o ccur in var ious solid tumo rs with the  highest rates in br east (27%), endom etrial 
(24%), bladder (23%), colon (15%) and ovarian (10%) cancers27-29. In addition to direct 
mutations  of PI3Kα, the pathway may also be activated by [CONTACT_299715] (RTKs) in cluding hum an epi[INVESTIGATOR_299667]  2 (HER2), epi[INVESTIGATOR_299668] (EGFR) and insulin- like growth factor 
receptor (IGFR). PIK3CA is also amplif ied in several tumor  types including the squamous type 
of NSCLC30. 
 
TAK- 117, a selective, small molecule inhibi tor of PI3K, has demonstrated greatest 
antiproliferative activi ty in cell lines harboring PIK3CA activ ating mut ations  and/or  HER2 
overex pression. TAK-[ADDRESS_365685] the remaining Class I PI3K isoforms (PI3Kβ, δ and γ) and mTO R. 
2.3 TAK-228 in  Comb ination with TAK-117 (PI [INVESTIGATOR_299658]) 
The nonc linical  antitumor activit y of TAK- [ADDRESS_365686] ream  cellula r signaling of the PI3K/AKT/mTOR  
pathway, western blot analysis was performed using a div erse group of hum an tumor  cell lines 
treated with PI[INVESTIGATOR_299669] a single agent or in combin ation. The t reatme nt of PI[INVESTIGATOR_299670]. Additiona lly, treatment with PI[INVESTIGATOR_299671], as indicated by [CONTACT_299716] (poly ADP  ribose  
polymerase). Further, the antiproliferative effect of PI[INVESTIGATOR_299672] a diver se 
group of human tumor cell lines in vitro and in vivo. The combina tion exhibite d at least additive 
activit y in all other cell lines tested (HCC1419, H CC1954, MDA -MB-468, MDA -MB-436 
[breast tumo r], A549, N CI-H460 and N CI-H596  [lung carcinom a]). The level of inhibition 
observed was greater for PI[INVESTIGATOR_299673]. Antitumor  activit y of 
PI[INVESTIGATOR_299674]:  two breast cancer cell line models, 
HCC70 (triple negative breast cancer, PTEN  null) and MDA- MB-361 ( HER2 amplif ied breast  
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 17 
X31025 Protocol Version  4 24-January- 2020  cancer with mutated PIK3CA), and one c olorectal cancer model, HCT-116 (KRAS and PIK3CA 
mutations ). The t reatment of PI[INVESTIGATOR_299675] a statistically significant 
(p<0.001)  increase  in antitumor  effects when compared with  single-agent treatment in multiple  
treatme nt schedules in th ese xenograft mod els. 
 
The p rincipal adverse effects associated with the administra tion of each agent are consist ent 
with their respective  mechanisms  of action. B ased on the available single-agent nonclinical and 
clinical  safety data for PI[INVESTIGATOR_299658], the expected overlappi[INVESTIGATOR_299676] 
(including bo ne marrow and lymphoid depletion, effects on glucose/insulin hom eostasis 
including  hyperglycemia, and potential effects on chloride and cholesterol levels) can be 
monito red with routine  clinical hematology and serum chemistr y evaluations, and are expected 
to be reversible and manageable in  the clinic. Results from  in vitro drug m etabolism  and 
pharmacokine tic studie s sugg est that the pot ential for DDIs between PI[INVESTIGATOR_299677] l ow. 
 
For detailed information regarding the nonc linical  pharmacology of PI[INVESTIGATOR_299678]. 
3. SUMMARY O F CLINICAL  EXPERIENCE  
3.[ADDRESS_365687] of TAK-228 on QTc interval in patients with advanced 
solid  malignancies. It is also being investigated in combina tion with paclita xel (with or 
without  trastuzumab) in patients with advanced solid  tumo rs (Ph1 study INK128- 003), and in 
combina tion with e xemestane or fulvestrant in women with ER+/HER2− (estrogen receptor -
posit ive/hum an epi[INVESTIGATOR_299679] 2  protein-negative) advanced or metastatic 
breast c ancer (Ph1b/2 study  C31001) . 
 
TAK- 228 dosing regimens tested in these studi es included QD, QW, QD× 3 days per week (once 
daily for 3 consecutive  days follow ed by a 4-day dosing holida y every week), and QD ×5 
days per week (once daily for 5 consecutive  days follow ed by a 2-day dosing  holida y every 
week). 
 
A new TAK- 228 capsule  containing  mille d active pharmaceuti cal ingredient (API) was 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 18 
X31025 Protocol Version  4 24-January- 2020  developed to allow scaled-up produc tion. The mi lled API, could result in a faster absorption 
profile with possibl y higher maximum concen tration (Cmax), which could present a differe nt 
safety profile compared to the previous  unmill ed API [CONTACT_162293] s. Therefore, an additiona l study: 
A Phase I, open label study to evaluate the safety , tolerability , and phar macokine tics of TAK-
228 as a single agent and in combina tion with paclitaxel  in adult pa tients with advanced non-
hematological malignancies  (study TA K-228-1004) , was designed to determine  the 
recomm ended phase 2 dose (RP2D) for single agent mille d TAK- 228 (QD and QW) and 
QD× 3day s per week in combina tion with paclitaxe l, as well as the effect of  high-fat meal on the 
PK of mille d API. 
 
The followi ng Table summ arizes TAK- 228 doses, schedules, active pharmaceuti cal ingredient 
(API) and PK popul ation investigated in all studies. Details on  PK and safety information for 
each stud y are availa ble in the  current  IB edition. 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 19 
X31025 Protocol Version  4 24-January- 2020  3.2 Clinical Experi ence  with TAK-117 
TAK- 117 is currently being investigated both as a single agent and in combina tion with 
chemoth erapy or other targeted therapi[INVESTIGATOR_299680]. As of the 
clinical  data cutoff date (22 June 2015) , the safety, tolerability, and PK data of si ngle- agent 
TAK- 117 evaluated in one FIH, dose-finding  study in patients with advanced non-hematologic 
malignancies (Study INK1117 -001) is  available in  the IB. Three additiona l clinical  studi es 
(MLN1117-1002, MLN1117 -1003 and MLN1117 -1501 ) are ongoing. A tabular summ ary of the 
studies is p resented below. 
 
TAK- 117 is  also being inve stigated in combi nation with  TAK- 228 in  study C32001 as 
described in the  followi ng section. 

PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 20 
X31025 Protocol Version  4 24-January- 2020  Sum mary of TAK-117 Clinical Studies 
Study No. Study Design/Population Dosing Regimen / 
Dose (Number of patients) Status 
 
INK1117 -001 
 
Phase 1  
Open-label, multicenter, dose-escalation / 
Adult patients (aged ≥18 years) with advanced solid 
tumors  
Process A capsules: 
• QD: 100, 150, 200, 300 mg (n=24) 
• MWF QW: 200, 300, 400, 600, 900, 1200 mg (n=27) 
• MTW QW: 200, 400, 600, 900 mg (n=20) 
Process B capsules: 
• MWF QW: 600, 900, 1200 mg (n=13) 
• MTW QW: 600, 900, 1200, 1500 mg (n=15) 
• BID on MWF QW: 300, 400, 500, 600 mg (n=22)  
 
Enrolling 
 
MLN1117 -1003  
Phase 1b Open-label, multicen ter, 4-arm combination, dose- escalation/ 
Adult patients (aged ≥18 years) with advanced or metastatic 
gastric or gastroesophageal adenocarcinoma 
• Part 1: lead-in dose escalation in patients with 
advanced solid tumors, including gastric cancer 
• Part 2: expansion at MTD or RP2D CohortsA-C(28-daycycles): Enrolling 
o TAK-659 (PO QD each week) 
+MLN1117 (MTW QW) 
o Alisertib (40 mg PO BID MTW, Wks 1-3) 
+MLN1117 (MTW QW) 
o Paclitaxel (80 mg/m2 IV M QW, Wks 1-3) 
+MLN1117 (TWTh  QW) 
Cohort D (21-day cycles): 
o MLN1117 (MTW QW) 
+docetaxel (75 mg/m2 IV M, Wk 1 only) 
 
MLN1117-1501  
Phase 1b/2  
Adaptive, open-label 2-arm dose-escalation / 
Adult patients (aged ≥18 years) with advanced or 
metastatic NSCLC 
 
● Part 1: dose escalation 
●  Part 2: sequential, multistage, adaptive, randomized 
phase 2 expansion at MTD or RP2D  
21-day cycles: 
● Escalation: MLN1117 (TWTh QW) 
+docetaxel (36 mg/m2 IV M, Wks 1-2) 
● Expan sion (2 treatment arms): 
o MLN1117 (TWTh Wks 1-3) 
+docetaxel (36 mg/m2 IV M, Wks 1-2) 
o Docetaxel single agent (75 mg/m2 IV M, Wk 1 only)  
Enrolling 
 
C32001  
Phase 1b Multicenter, open-label, safety, and PK. 
Adult patient (aged ≥ 18 years) with advanced 
nonhematologic malignancies 
 
• Dose escalation (3+3) 
• Expansion (mutual PK DDI;  tumor-specific 
cohorts) 28-day cycles: 
o Escalation: (includes milled TAK-228) 
o Arm A: TAK-228 QD+ TAK -117 
QD x3d (MWF) QW 
o Arms B & C: TAK-228+TAK- 
117 QDx 3d (MTW) QW 
o Expansion: (2 arms) 
o TBD per escalation Enrolling 
Abbreviations: BID=twice daily, EU=European Union, IV=intravenous, M=Monday, MTD=maximum tolerated dose, MTW=Mond ay, Tuesday and Wednesday, MWF=Monday, Wednesday and Friday, 
NSCLC=non-small cell lung cancer, PO=orally, QD=once daily, QD= once daily, QW=each week, RP2D=recommended phase 2 dose, TWTh =Tuesday, Wednesday and Thursday, [LOCATION_006]=[LOCATION_008], 
US [LOCATION_002], Wk(s)=week(s). 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 21 
X31025 Protocol Version  4 24-January- 2020  3.3 Clinical Experi ence  with TAK-228 + T AK-117 (PI[INVESTIGATOR_299681]; study C3200 1) 
As of the clinical  safety data cutoff date (10 March 2015) , PI[INVESTIGATOR_299682] 
1 pha se 1b stud y (Study C32001) . This stud y is a multicent er, ope n-label, phase 1b trial of 
PI[INVESTIGATOR_299683]- hematologic malignancies for whom  
standard, curative, or life-prolonging anticancer treatment does not exist or is no long er effectiv e. 
 
PI[INVESTIGATOR_299684] 28-day dosing cycles, in weekly regimens of TAK -228 
QD+ TAK-117 QDx 3d (MWF) (Arm A) and TAK- 228+ TAK117  QDx 3d (MTu W) (Arms B 
and C ). 
 
As of the data cutoff, a total of [ADDRESS_365688] 1 dose of TAK- 228 or TAK- 
117 in S tudy C32001 a nd are included in the  Safety Population. 
3.3.1 Pharmacokinetics  
Preliminary PK data from study C32001 sugge sts that TAK -228 exposures increase with dose 
in the 2  to 8 mg dose range and appear variable across  the various  cohorts  (%CV range across 
all cohorts: 16 -90%). TAK -[ADDRESS_365689] of thes e agents on each other’s PK when combined.  
 
Please refer to the TAK -228 IB and (TAK -[ADDRESS_365690] been 
analyzed. Expression of all markers (pS6, p4EBP1 and pNDRG1) in skin was suppressed  
>50% compared to the pre -dose level in a majori ty of patients in all treatment arms with  >80% 
suppression of markers in a subset of patients when measured approximate ly [ADDRESS_365691] -
dose on Cycle 1 Day 24.  Based  upon  the time course of PD  data available there  appeared to 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page [ADDRESS_365692] (up t o [ADDRESS_365693] -dose) at TAK -[ADDRESS_365694] recent IB (10 March 2015), the two agents had been 
co-administered in a single open -label, pha se 1b study (Study C32001) in patients with 
advanced non -hematolog ic malignanci es. A total of 44 patients had been treated; 11 were 
ongoing. One on -study death was reported in a patient with a fatal event of dyspn ea, which 
was considered by [CONTACT_299717]. A total of 12 treatment - 
emergent SAEs were reported for 9 patients (20%); all SAEs were clas sified as unrel ated with 
the exception of 1 related SAE of Grade 3 enterocolitis. Five patients had discontinued due to 
TEAEs (three wi th related AEs). The most frequently reported TEAEs, regardl ess of causali ty, 
were nau sea, fatigue, diarrhea, vomiting, decrea sed appetite, increas ed aspar tate 
aminotransferase, stoma titis, ALT, constipation a nd maculopapular rash.  
3.3.[ADDRESS_365695]  common  TEAEs  observed with TAK -228 are consistent  with the pharmacodynamic 
mechanism of mTOR inhibition that is also seen  with rapalogs (TORC1 inhibition) or other 
dual mTORC1/[ADDRESS_365696], as well as more detailed information on the identified 
and potential risks of both drugs is included in the individual single -agen t IBs  and in the 
PI[INVESTIGATOR_299685]. 
  
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 23 
X31025 Protocol Version  4 24-January- 2020  Potential overlappi[INVESTIGATOR_299686] -228 and TAK -117 include:  
• Dermatologic disorders (pruritus and rash)  
• Gastrointestinal disorders (diarrhea, mucosal inflammation, nausea, stomatitis and 
vomiting)  
• Generalized disorders (anorexia, asthenia, decreased appetite and fatigue)  
• Hematologic disorders (lymphoid and bone marrow depletion)  
• Metabolic  disorders  (decreased  blood chloride, hypercholesterolemia and 
hyperglycemia)  
On the basis of current clinical  experience and the p revious  list of potential overlappi[INVESTIGATOR_123439], hyperglycemia, diarrhea, n ausea, vo mitin g, fatigue, and rash are the most a nticipated 
TEAEs  associated with the TAK -228 + TAK -[ADDRESS_365697] application of  
the study inclusion and exclusion criteria, frequent monitor ing of clinical  and laboratory results,  
guidelines for management and prophylaxis of potential toxicities, criteria for dose modi fication,  
and regular monito ring of TEAEs  and serious adverse events (SAEs)  by [CONTACT_456] . 
4. SPECIAL  WARNI NGS AND PRE CAUT IONS 
4.[ADDRESS_365698] self-monito ring of  blood glucose, a finding  of 
fasting blood g lucose ≥ 150 mg/dL measured by [CONTACT_299718] e intervention. Subjects with Grade 1 hyperglycemia (fasting serum 
glucose [FSG] > the uppe r limit of the normal range ≤160 m g/dL) are treated with oral 
hypoglycemic agents (e.g., metformin), and subjects with ≥Grade 2 hyperglycemia (FSG 
>160 mg/dL) are treated aggressively with  oral hypoglycemic agents and/or insulin  as clinical ly 
indicated. Daily home  monitoring and early treatm ent have resulted in good control of glucose 
levels for the majority of TAK-228-treated subj ects who d eveloped hyperglycemia. Guid elines 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page [ADDRESS_365699] s 
Cardiac events (including QT interval corrected for heart rate prolongation and arrhythmia s) 
have been infrequently obs erved in clinical  studi es of TAK- 228. As of [ADDRESS_365700] dose tha t had a fatal outcome 
and w as assessed as related to TAK-228 ( see IB for further details). 
 
Prelimin ary results from  a dedicated stu dy of the effects of TAK- 228 o n the QTc interval (study 
C31002)  show  lack of clinical ly relevant effects on QTc interval, PR and QRS intervals, minima l 
effects on heart rate, and absence of treatment-emergent ECG mo rpholo gy findings and therefore 
the treatment with TAK- 228 is not associated with clinical ly meaningful effects on the overa ll 
electrocardiographic safety profile (for further de tails ref er to the  current IB version). 
 
For subjects showing  any signs of cardiac instability after TAK-[ADDRESS_365701] ion 
Elevations  in creatinine  (regardless of causality) have been observed in subjects receiving 
TAK- 228, all of which have been reversible  with drug int erruption and/or suppor tive care with 
IV hydration. Further evaluation of the renal insufficiency with  urine electrolytes sug gested a 
pre-renal etiology with a low fractional excretion  of sodium  < 1%. Howe ver, the adverse event 
cases were confound ed by m ultiple  facto rs such as nausea, vomi ting, hyperglycemia, 
concomitant medications  with GI side effects such as metformin and hydronephrosis, any of 
which may have also contributed to dehydration and elevated creatinin e. Patients should be 
encouraged to drink at least 20 ounces of fluids  a day, especially on days requiring fasting (per 
protocol), with administra tion of IV fluids  in the c linic as indicated to avoid dehydration. Each 
dose of TAK- 228 should be taken orally with 8 ounces ( 240 m L) of water. 
 
Baseline macroscopic urinalysis and routine s erum chemistr ies along with other safety 
laboratory assessments are performed in all TAK-228 studi es. Addit ionally, microscopic 
urinalysis, a 12-hour urine collection, spot urine electrolytes, protein and creatinin e, and serum 
chemistr y should be collected at any time when the serum creatinine  is ≥Grade 1, accor ding 
to National Cancer Institute  Common Terminolo gy Criteria for Adverse Events ver sion 4.0, 
to further evaluate possible  etiologies for the renal dysfunction. 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 25 
X31025 Protocol Version  4 24-January- 2020  4.4 Rash  
Rash observed in clinical  studi es of TAK- 228 tends to be maculopa pular and pruritic and ha s 
ranged from G rade 1–3. For the most par t, rash and pruritus imp rove with a ntihista mines, topi[INVESTIGATOR_299687], and/or  dose int erruption. Some subj ects have required pulse  systemic steroids, 
dose reduction, a nd/or  study treatment dis continua tion. 
4.[ADDRESS_365702] not been conducted with TAK- 228. At this time, there 
are no known drug interactions. In vitro data, including cytochrome P450 induction/inhibition 
and transporter inhibition studies conducted for TAK -228, suggest a low risk for TAK -228 to 
precipi[INVESTIGATOR_047] a drug -drug interaction. Although potential drug -drug interactions with TAK -228 
cannot be ruled out based on the known metabolism characteristics of TAK -228, the potential 
risk is considered low.  
5. RAT IONAL E FOR T HE RP2D FOR PI[INVESTIGATOR_299681] (TAK-228 + TAK -117) 
Study C32001 is an ongoing o pen-label study designed to determine  the MTD and DLTs for 
oral administra tion of mille d TAK-228 given in combina tion with TAK- 117 and was designed 
to characterize the safety and tolerability  of escalating doses of TAK -228 and/or TAK -117 in 
patients with advanced solid  tumo rs. The study features a dose-escalation phase evaluating 3 
dosing  schedules. A favorable tolerabilit y profile was observed when increasi ng dos es of TAK-
228 (3–8 mg) were administ ered with a fixed dose of TAK- 117 (both given QD × 3QW). The 
MTD for TA K-228 in combin ation with  TAK-117 both given QD ×  3 QW  was 6 m g TAK-228 
+ 200 m g TAK-117. 
  
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 26 
X31025 Protocol Version  4 24-January- 2020  Table Dose  Limiting Toxicity Observed with TAK-228 + TAK-117 (3 Days  Per Week) in 
Study C32001 
 
 
While both combina tion dose  levels were conside red safe based on 3+3 rules, the  lower dose 
level of 4 mg + 200 mg QD × 3 QW was chosen as the RP2D for milled TAK228 + TAK- 117 
for further developm ent. 
6. STUDY RAT IONAL E 
Activation of the PI3K/AKT/mTOR  axis (Figure 1; slide  9 in ref. 33) has been implicat ed as 
playing an impo rtant role in the tumo rigenesis process in many malignancies34. Activation of  
this pathway through mutation of various genes directly involve d in pathway activ ation or 
through mutation of the suppre ssor PTEN  result in activ ation of this signaling axis. We 
propose  that inhibito rs of this pathway in combina tion with chemotherapy might be efficacious 
in the  treatme nt of advanced solid tumor s. 
 
It is hypothe sized that blocking both TORC1 and TORC2 compl exes is more effective at 
preventing activation of AKT  than inhibiting  AKT  through TORC1 compl ex inhibi tion a lone33. 
In this regard, TAK- 228 is a selective mTOR  inhibitor th at blocks both TO RC1/TO RC2-
compl ex activit y. In a clear-cell Renal Cell Carcinoma (ccRCC)  xenograft mod el, TAK- 228 was 
more effective th an everolimus,  a TO RC1 complex inhibitor, at inhibiting  tumor  growth  in vivo 
(slide  3 in ref. 33). Howe ver, it was also shown  that TAK- 228 inhibition  of TORC1/TO RC2 
resulted in a rapid but transient inhibition of AKT phosphor ylation and AKT signaling. 
Inhibition of PI3Kα with TAK-[ADDRESS_365703] ete inhibition  of 
tumor  growth  in the ccRCC  xenograft mode l than with TAK- 228 a lone (slides 8–10 in ref . 33). 

PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 27 
X31025 Protocol Version  4 24-January- 2020   
Figure 1. Sustained inhibition  of PI3Ka, TORC1 and TORC2 may be required to be mo re 
effective th an sustained TORC1 and TORC2 inhibi tion to maximize cance r growth inhibitor y 
effects. 
 
The mechanisms  by [CONTACT_299719]. 
Evid ence suggests, however, that activ ation of the PI3K/AKT/mT OR pathway by [CONTACT_299720] a role35-37. Conver sely, PI3K inhibito rs have been shown to sensitize tumo rs to the 
effects of paclita xel37-39. In one study by [CONTACT_299721].40, they found that by [CONTACT_299722]3Ks th ey 
could regulate mitotic progression  and prevent mitotic  cell death. Therefore, the link be tween 
taxane resistance and activ ation of the PI3K/AKT/mTOR  signaling pathway sug gests that by 
[CONTACT_299723]-mitotic drugs like paclita xel may also imp rove 
treatment out comes in advanced solid tumor s. 
 
Therefore, the rationale for using this  combina tion is that TAK-[ADDRESS_365704] ete blockade of the PI3K/AKT/mTOR  pathway. 
This approach may represent a promisin g combina tion to employ as targeted therapy in the 
treatme nt of advanced solid  tumo rs. We propose  to combine  TAK- 228 with TAK- 117 and 
paclita xel in a phase I trial to determine  the safety profile of this combin ation in a dvanced solid 
tumo rs. 

PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page [ADDRESS_365705] 
Symptom  occu rrence and severity of therapy-related symptoms  and health -related qua lity of life 
(HRQOL) will be described for patients unde rgoing the  treatme nt regimen described on this 
study. 
 
The Th erapy-Related Symptom  Checklist ( TRSC) is a patient self-report tool that allows  for the 
subjective measurement of the rapy-related symptom  severity41. Patients rate 25 s ymptoms  on 
severity using a five-point  scale; other symptoms  may be added and ra ted as well. A higher total 
score on the TRSC indicates greater frequency and severity of symptoms.  Prior studi es have 
indicated that TRSC scores correlate inversely with  the K arnofsky Performance Scale (KPS) and 
have led to improved symptom  documentation and m anagement, thereby [CONTACT_299724] g patients’ 
quality of life42. The TRSC has shown  good internal  consistency and reliabili ty with a 
Cronbach’s  alpha of at  least  0.[ADDRESS_365706] validity is evidenced b y previous  
correlations  between TRSC scores and clinician-rated Karnofsky scale, as well as scores on a 
quality of life index. 
 
Patient health -related quality of life (HRQOL) will be assessed using  the Health-Related Quality 
of Life Linear Analogue Self-Assessment (HRQOL-LASA). The HRQOL-LASAS m easures six 
items on a 10-point  scale from  0 (as bad as can be) to 10 (as good as can be). These items have 
been validated as measures of global QOL constructs in numerous settings43-47. 
 
Potential B iomarkers 
Most  patients who enter this study will have had or will have genomic  sequencing performed. 
For patients who have had sequencing compl eted and for whom  results are available, correlations 
with response  and pre sence of the genomic  alterations  will be a ssessed. 
7. STUDY O BJECTIVES 
7.[ADDRESS_365707] ive 
• The primary  objective  is to determine  the maximum tolerated  dose of the 
combination of TAK -228, TAK -[ADDRESS_365708] ive 
• To determine the objective response rate (according to RECIST 1.1 response 
criteria)  
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 29 
X31025 Protocol Version  4 24-January- 2020  7.3 Tert iary/Exploratory Object ives 
• To ass ess whether patients with genomic alterations responded more favorably to 
the combination 
• To describe symptom  occurrence and severity  of therapy -related  symptoms  and 
Health Related Quality of Life (HRQOL) as measured by [CONTACT_299707]  - 
LASA respectively  
8. STUDY E NDP OIN TS 
8.1 Prim ary Endpoi nts 
• Safety evaluation  
• Patient tolerance  
8.2 Secondar y Endpo int 
• Objective tumor response (according to RECIST 1.1 response criteria)  
8.3 Tert iary/Exploratory Endpoint s 
• Symptom occurrence and severity of therapy -related symptoms and Health Related 
Quality of Life (HRQOL) as measured by [CONTACT_299707] -LASA, 
respectively  
• To assess whether patients with genomic alterations respond more favorably to the 
combination 
9. STUDY DES IGN 
9.[ADDRESS_365709] exceeded 
the recommended phase 2 dose (R2PD). No MTD w as established, but the dramatic reduction 
in tolerability makes this dose and schedule unsuitable for long -term use. Thus, it was 
determined to proceed with a dose expansion of cohort 4 to further evaluate if this dose and 
schedule would be the eventual R P2D.
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 30 
X31025 Protocol Version  4 24-January- 2020  
Dosing  schema: (3–6 pts. per cohort) 
 
 
 
 
 
 
 
 
 
 
 
 
The goal of this study is to determine  a tolerated dose of the combina tion of TAK- 228, 
TAK- 117 and paclita xel. To do this, we  will estimate the maximum tolerated dose (MTD) th at 
is defined as the dose l evel at which less than one-third of patients will experience a dos e-limiting  
toxicity (DLT). A traditiona l dose escalation design will be used, beginning with  the lowest 
dose level and escalating to the maximum allowable dose level as specified in the protocol. 
Three patients will be treated one at a time at a given dose level. A maximum  of 5 dosing 
levels results in a maximum sample  size of n=30 subjects. Adverse events will be  defined using 
the Common To xicity Criteria v. 4.0.  
 
Cohort 1 Cycle 1 
Study Day 1 2-4 8 9-11 15 16-18 23-25 
Paclita xel 60m g/m2 X  X  X   
TAK -228 2m g  X  X  X X 
TAK -117 100m g  X  X  X X 
 
Cohort 2 Cycle 1 
Study Day 1 2-4 8 9-11 15 16-18 23-25 
Paclita xel 60m g/m2 X  X  X   
TAK -228 2m g  X  X  X X 
TAK -117 200m g  X  X  X X 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 31 
X31025 Protocol Version  4 24-January- 2020  Cohort 3  Cycle 1 
Study Day 1 2-4 8 9-11 15 16-18 23-25 
Paclita xel 80m g/m2 X  X  X   
TAK -228 2m g  X  X  X X 
TAK -117 200m g  X  X  X X 
 
Cohort 4 Cycle 1 
Study Day 1 2-4 8 9-11 15 16-18 23-25 
Paclita xel 80m g/m2 X  X  X   
TAK -228 3m g  X  X  X X 
TAK -117 200m g  X  X  X X 
 
Cohort 5 Cycle 1 
Study Day 1 2-4 8 9-11 15 16-18 23-25 
Paclita xel 80m g/m2 X  X  X   
TAK -228 4m g  X  X  X X 
TAK -117 200m g  X  X  X X 
 
DLT is d efined as: 
• Any death not clearly due to underlying disease or extraneous causes  
• Hy's Law 
o Subjects with AST or ALT elevations > [ADDRESS_365710] and total bilirubin elevation >[ADDRESS_365711] without initial findings of cholestasis (elevated serum alkaline 
phosphatase)  
• Grade 3 or higher non-hematologic toxicity, despi[INVESTIGATOR_42209], except  for the  
followin g: 
o Grade 3 hyperglycemia lasting  ≤14 days (all patients  should receive optimal 
antiglycemic treatment, including insulin, as clinically indicated)  
o Grade 3 rash lasting  ≤3 days (all patients should receive  topi[INVESTIGATOR_299688], 
oral antihista mines, and oral steroids, if  necessary)  
o Inadequatel y treated Grade 3 nausea and/or  vomiting  and Grade 3 diarrhea (all 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 32 
X31025 Protocol Version  4 24-January- 2020  patients should receive  optima l antiemetic and/or antidiarrheal prophylax is and/or 
treatme nt) 
• Patients experiencing any Grade 3 or more hematologic toxicity attributed to the 
treatme nt will hold all therapy until resolution of the toxicity to Grade 1 or baseline 
levels.  If toxicity persists,  the p atients will be removed from  the stu dy. Upon  resolution 
of the t oxicity, the p atient will restart treatment at the original dose  at the discretion of  
the inve stigators.  No dose adjustments are allowed during the DLT phase of the study.  
• Grade 4 neutropenia lasting >7 days in the absence of growth factor support  
• Grade 4 neutropenia of any duration accompanied by [CONTACT_411] ≥38.5°C and/or systemic  
infection  
• Grade 3 thrombocytopenia with bleeding 
• Grade 4 thrombocytopenia > 7 days  
• Any othe r ≥Grade 4 hematolo gic toxicity 
• Inability to administe r at least 75% of planned doses of TAK-228 within  Cycl e 1, due  
to stu dy drug-related to xicity 
• Any clinically significant occurrence that the investigator and sponsor agree would 
place patients at an undue safety risk  
 
Patients experiencing any adverse event that requires drug to be held should return to Grade 1 or 
baseli ne before resuming therapy at the current or a reduced dose.  Rash and hyperglycemia are 
permitted exceptions in which therapy may be resumed at Grade 2 or less.  
 
One of the followi ng outcomes will d etermine  the treatme nt of subs equent pa tients: 
• If none  of the three patients experiences a DLT, the next group of patients will be entered 
in the next higher dose cohort. All patients within  a cohort must  have compl eted at least 
once cycle (28 day s) prior to initia tion of the next cohort of patients. 
• If one of the three patients experiences a DLT, three more patients will be accrued at the 
current dose level. Subsequently, if only one of the six patients treated at this level 
experiences a DLT, the dose will be escalated to the next higher dose in the next group  
of patients. If two or more of the six patients experiences a DLT, the MTD has been 
exceeded and is defined as the previous dose at which no more than 1/3 experienced a 
DLT.  
• If at least two of the three experience a DLT, the MTD  has been exceeded  and is defined 
as the previous dose  at whi ch no mor e than 1/[ADDRESS_365712] allowable dose level exceeds  the MTD,  the study will be terminated and the 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page [ADDRESS_365713], if applicable. 
 
Growth factor support may be utilized at the discretion of the PI, but may not be used 
prophylactically in cycle 1. All other routine supportive care may be used in Amendment 3. 
9.2 Study Procedures  
Screening Procedures/Enrollment  
All subjects must  have signed and dated the informed consent and HIPAA Author ization pr ior 
to any study specific screening procedur es being performed. Pre-enrollment screening t est and 
evaluations  will be used to determine  the eligibilit y of the patient for study inclusion. All 
screening  tests and procedure s must  be compl eted within  30 days prior to stu dy registration 
and inc lude the followin g: 
1) Demography and M edical Histo ry including documentation of  prior regimen 
2) Physical exam including he ight and weight 
3) Vital signs inc luding : temperatu re, BP, puls e, respi[INVESTIGATOR_143344] 
4) Concomita nt medications  
5) Performance Status–-ECOG 
6) CBC with di fferential and platelet count (CBCD)  
7) Coagulation Panel (PT/INR, aPTT)  
8) Urinalysis  (UA)  
9) Comprehensive Metabolic Panel  (CMP):  ALT/SGPT, AST/SGOT, LDH, phosphorus, 
magnesium, calcium, total protein, a lkaline phospha tase, total bilirubin (direct and 
indirect  bilirubin if total bili is abnormal) , HbA1C, fasting glucose, fasting  lipid panel  
(Total cholesterol, HDL -C, LDL -C, triglycerides) , creatinine  clearance (calculated 
using  the Cockcroft formula) or creatinine  and albumin  
10) Serum pr egnancy test, required onl y for wom en of child-bearing potential 
11) Electrocardiogram 
12) Tumor  Assessment 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 34 
X31025 Protocol Version  4 24-January- 2020  Baseline 
The following ba seline assessments are to be performed within  14 days prior to starting 
recomm ended treatme nt. Screeni ng clinical  evaluations  and laboratory assessments may be used 
as the baseline evaluations  if they are done  within  14 days prior to starting recomm ended 
treatme nt. 
 
The investigator/treatin g physician will need to ensure that the patient’s baseline evaluations still  
meet eligibilit y criteria or will report any exclusiona ry criteria to a Clinical  Principal 
Investigator [INVESTIGATOR_299689]. 
• Physical exam including he ight and weight 
• Vital signs inc luding : temperatu re, BP, puls e, respi[INVESTIGATOR_143344] 
• Concomita nt medications  
• TRSC (see App endix 5) 
• HRQOL-LASA (see Appendix 6) 
• Performance Status-ECOG 
• CBC with di fferential and platelet count (CBCD)  
• Comprehensive Metabolic Panel  (CMP):  ALT/SGPT, AST/SGOT,  Alkaline 
Phospha tase, Total Bilirubin, HbA1C, fasting glucose, lipid panel, Creatinine 
Clearanc e (calculated using  the Cockcroft formula) or Creatinin e, and Albumin. All 
additional labs are at the discretion of the treating physician.  
• Baseline Tum or Assessment acco rding to RECIST 
o Scans must  be performed within  the 30 days prior to starting recom mended 
treatme nt 
• Pregnancy Test – to be  performed ≤[ADDRESS_365714] dose  of study drug 
•  
On-Study 
For the purposes of this stu dy the followi ng evaluations will be  performed: 
• Physical E xam 
• Vital Signs 
• ECOG p erform ance status 
• CBC with di fferential 
• Coagulation Panel (PT/INR, aPTT)  
• Urinalysis  
• Fasting lipid profile  every 3 cycles  
• HgbA1C every 3 cycles  
• Home g lucose monitoring if required , per Table 1 Schedule of Study Assessments  
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 35 
X31025 Protocol Version  4 24-January- 2020  • Fasting serum glucose on days patient receives paclitaxel  (prior to treatment only)  
• Compre hensive  Metabolic Panel to include full electrolyte panel with calcium, 
phosphate, and magnes ium, LFTs, kidney function tests, total bilirubin ( direct bilirubin  
if total bili is abnormal) , total protein  
• ECG 
• Tumor  Assessment accor ding to RECIST 1.[ADDRESS_365715] cycle, and then every 12 ± 1 week until study discontinuation or disease 
progression, whi chever is later. (See Section 7.2)  
• TRSC and H RQOL-LASA 
• Adverse events will be assessed at every visit.  Adverse events will be graded according 
to NCI-CTCAE, version 4. For the purposes of this study only the following  adverse 
events will be  reported: 
o Any grade ≥3 adverse event  
o Any adverse event resulting in tr eatment dose reduction or discontinuation  
o Any adv erse event considered by [CONTACT_299725]/treating physician to 
be medically signifi cant 
o Any serious adv erse ev ent 
End of Treatme nt 
At the time the p atient discontinue s the recomm ended treatme nt for dis ease progression  or any 
other reason the following  assessments are to be performed within  [ADDRESS_365716] dose of  
treatme nt: 
• Physical exam  
• CMP and CBC D (labs as described previously)  
• Urinalysis  (UA)  
• Fasting lipid profile  
• Fasting serum glucose  
• Tumor  Assessment according to RECIST 1.1 ( see Section 7)  
• ECG 
• Coagulation Panel (PT/INR, aPTT)  
• Tumor  markers for those  patients who ha d elevated tumor  markers on l ast prior regimen 
• Concomita nt medications  
• TRSC  
• HRQOL-LASA 
• Assessment of adverse events ongoing at study discontinua tion. Adverse events will be  
graded accor ding to NCI-CTCAE, version 4. For the purposes of this study only the  
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 36 
X31025 Protocol Version  4 24-January- 2020  following  adverse events will be  reported: 
o Any grade ≥3 adverse event  
o Any adverse event resulting in treatment dose reduction or discontinuation  
o Any adverse event considered by [CONTACT_299726]/treating physician to be 
medically si gnificant  
o Any serious adverse event  
• Reason for discontinua tion is to be documented in patient sourc e docum ents and 
recorde d on CRF  
• Any new primary malignancies must be reported to [COMPANY_005] if occurring within 3 years 
from study initiation  
Follow-Up 
All patients will be contact[CONTACT_299727] 4, 8, 
12, 18 and 24 months.  For those pa tients without  disease p rogression  at the end of therapy, tumor  
assessments will be under taken every 3 months  until either disease progression  is obs erved or 
further anti-cancer treatm ent is initia ted. 
 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 37 
X31025 Protocol Version  4 24-January- 2020  Table 1. Schedule of Study Assessments 
  Cycle 1 Cycle 2 Cycle 3-8 Subse quent cycles  
Assessments1 Screening 
Day -30 to  
Day -1 C1D1 C1D8 C1D15  C1D22  C2D1 C2D8 C2D15  C2D22  D1 D15 D1 Termination 
Demographics 
and Medical 
Hi  X 
            
Physical 
Exam2 X X X X X X X X X X X X X 
ECOG PS X X    X    X    
Vitals X X X X X X X X X X X X X 
Hematology3 X X X X  X X X  X  X X 
Chemistry3 X X X X  X X X  X  X X 
Serum 
pregnancy 
tt (if  
 X X            
Coagulation 
Panel  X X    X    X   X 
ECG5 X  X 
HbA1c X X        C3D1  C6 and q3 cycles  
In home 
fasting 
l  
  Daily pre-dose from cycle [ADDRESS_365717] dose of study drug (may be decreased to once a week 
after the first 2 cycles , as detailed in Manag ement of Hyperglycemia – section 12.3.1)   
Urinalysis X X  X  X    X  X X 
TRSC  X    X    X  X X 
HRQOL -LASA  X    X    X  X X 
AE 
assessment  X X X X X X X X X X X X 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 38 
X31025 Protocol Version  4 24-January- 2020    Cycle 1 Cycle 2 Cycle 3-8 Subse quent cycles  
Tumor 
Assessment7 
(per RECIST 1.1) 
and/or t umor 
  
 X         To be  completed 
prior to cycle 4  and 
then every 12 weeks  
 Every 3 cycles at the discretion of the 
investigators   
1 With the excep tion of ECGs, assessments may be done  within 24-48 hours of dosing with drug administration. 
2 Symptom directed.  
3 Labs as listed in the protocol (section 9.2.1) .  Labs that are drawn on clinic days should be drawn while fasting.  Patients are required to 
fast overnight prior to all chemistry panels and must include a blood glucose.  
[ADDRESS_365718] will be performed for females that are of childbear ing potential, and will need  to be performed ≤[ADDRESS_365719] 
dose of study drug 
5 Single, 12-lead ECG will be collected  at screening (within [ADDRESS_365720] dose), EOT and as clinically indicated while on protocol 
therapy .  
6 Patients will be given a glucometer to monitor fasting glucose levels at home collected  daily, pre-dose only on dosing days of the TAK 
228 and TAK 117 , at approximately the same time each day a nd will be instructed  to notify the study staff any time the fasting glucose 
is abnormal (≥150mg /dL and <160 mg/dL ). In-home glucose monitor ing is not required on days when fasting glucose is measured in the 
clinic. For further instruction see Management of Hyperglycemia section (section 12.3.1) . 
[ADDRESS_365721] 1.1 will be performed at baseline (within 30 days before entering the study), at the end of the third cycle, 
and then every 12 ±1 week until study discontinuation or disease progression, whichever is later.  
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 39 
X31025 Protocol Version  4 24-January- 2020  9.3 Numbe r of Patients 
Total numbe r of patients to be enrolled, 2–30. A patient is considered enrolled on the first 
day of paclita xel treatme nt. 
9.[ADDRESS_365722] mee t all of the following  inclusion cr iteria to be  enrolled in the  study: 
1. Male or female patients [ADDRESS_365723] a diagnosis of  an advanced solid tumor  malignancy that is 
refractory to or intolerant of existing therapy(ies) known to provide clinical benefit for 
their condition 
3. Eastern Coope rative Oncology Group ( ECOG) perfor mance status and/or othe r 
performance status of  0-2 
4. Female patients who:  
a. Are postm enopa usal for at least [ADDRESS_365724] 
and agree to practice one effective  method of pregnancy prevention 
contraception a nd one  addition al effective (barrier) method, a t the same time , 
from  the time of sig ning the informed consent through 90 days (or longer as 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 40 
X31025 Protocol Version  4 24-January- 2020  mandated by [CONTACT_299728] [e.g., USPI, SmPC, etc.,]) after the last dose of 
study drug, OR  
d. Agree to practic e true abstinence, wh en this is in line  with the  preferred and 
usual life style of t he patient. (Periodic abstin ence [e.g., calendar, ovulation, 
sympto -thermal and post ovul ation m ethods ], withdra wal, spe rmicides only, 
and lactational amenorrhea are not  acceptable methods of contraception. Female 
and m ale condoms should not be  used tog ether.) 
5. Male patients, even if surgically sterilized (i.e., status post- vasectomy), who:  
a. Agree to practice highly effective barrier contraception during the entire 
study treatme nt per iod and thr ough [ADDRESS_365725] dose  of study drug, 
OR 
b. Agree to practic e true abstinence, wh en this is in l ine with the  preferred and 
usual life style of t he patient. (Periodic abstin ence [e.g., calendar, ovulation, 
sympto -thermal and post ovulation methods  for the fe male partner], withd rawal, 
spermicides only, and lactational amenorrhe a are not  acceptable methods of 
contraception. Fe male and male condoms should not  be used tog ether.) 
c. Agree not to donate sperm during the course of this study or within  [ADDRESS_365726] dose  of study drug 
6. Screeni ng clinical la boratory values as specified below: 
a. Bone marrow reserve consistent with: absolute neutrophil  count (ANC) ≥1.5 x 
109/L; platelet count ≥100 x 109/L; hemoglobin ≥9 g/dL without transfusion 
within 1 week preceding study drug administration  
b. Hepatic: total bilirubin ≤1.5 x upper limit of normal (ULN), transaminases 
(aspartate aminotransferase/serum gl utamic oxaloacetic transaminase-  
AST/SGOT and alanine aminotransferase/serum glutamic pyruvic 
transaminase- ALT/SGPT) ≤2.[ADDRESS_365727] (≤[ADDRESS_365728] if liver metastases are 
present);  
c. Renal: creatinine c learance ≥50 m L/min b ased either on C ockcroft-Gault 
estima te or based on ur ine collection ( 12 or  24 hour);  
d. Metabolic: Glycosylated hemoglobin (HbA1 c) <7.0%, fasting  serum glucose 
(≤ 130 m g/dL) and fa sting triglycerides ≤300 m g/dL 
7. Abilit y to swallow o ral medications  
8. Volunt ary written consent must  be given before performance of any study related 
procedur e not part of standard medical care, with the under standing that the patient may 
withd raw consent at any time without pre judice to future medical care 
9. Patients who have a history of brain metastasis are eligible for the study  provide d 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 41 
X31025 Protocol Version  4 24-January- 2020  that all the  following  criteria are met: 
a. Brain metastases which have been treated  
b. No evidence of disease progression  for ≥[ADDRESS_365729] dose  of TAK- 228 
e. No ong oing requirement for dexamethasone or anti-epi[INVESTIGATOR_006] 
10.2 Exclusion Criteria  
Patients m eeting  any of the following e xclusion cr iteria are not to be  enrolled in the  study: 
1. Active cent ral nervous s ystem (CNS) metastasis 
2. Other clinical ly significant co-morbiditi es, in the  opi[INVESTIGATOR_113576], such as 
uncontrolled pulmona ry disease, active  central nervous  system disease, active in fection,  
or any other condition that could compr omise  the patient’s participation in the  study 
3. Known hum an immunodef iciency virus infection  
4. Known  hepatitis B surface antigen-positiv e, or known or suspected active  hepatitis C 
infection  
5. Any serious medical or psychiatric illness that could, in the investigator’s opi[INVESTIGATOR_1649], 
potentially interfere with the  compl etion of  treatment acco rding to this p rotocol 
6. Diagnosed or treated for anothe r malignancy within [ADDRESS_365730] dose of 
study drug 
9. Previous  treatm ent with  PI3K, AKT,  dual PI3K/mTOR  inhibito rs, TORC1/ 2 inhibitor s 
(prior treatme nt with e verolimus is a llowed) 
10. Manifestations  of malabsorption due to prior gastrointestinal (GI) surgery, GI disease, 
or for an unkn own reason  that may alter the absorption of TAK- 228. In addition, 
patients with small bowel or jejunal  stom ata are also excluded. 
11. Histo ry of any of the following  within  the last 6 months  before administr ation of the 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page [ADDRESS_365731] dose  of the drug: 
a. Ischemic myocardial event, including  angina requiring t herapy and artery 
revascularization pr ocedures  
b. Ischemic cerebrovascular event, including  transient ischemic attack and artery 
revascularization pr ocedu res 
c. Requirement for inotropic suppor t (excluding  digoxin) or serious (uncontrolled) 
cardiac arrhythmia  (including atrial flutter /fibrillation, ve ntricular fibrillation or  
ventricular tachycardia) 
d. Placem ent of a pacem aker for control of rhythm 
e. [LOCATION_001] Heart Association (NYHA) Class III or IV heart failure (See 
Appendix B) 
f. Pulmona ry embolism 
12. Significant a ctive cardiova scular or pulmona ry disease including: 
a. Uncontrolled hypertension (i.e., systolic  blood pressure >180 mm Hg, diastolic 
blood pressure >95 mm Hg). Use of anti-hypertensive  agents to control 
hypertension be fore Cycle1 Day 1 is a llowed. 
b. Pulmona ry hypertension  
c. Uncontrolled asthma  or O2 saturation <90% by [CONTACT_299729] 
d. Significant valvular disease; severe regurgitation or stenosis  by [CONTACT_299730], or histo ry of valve 
replacement 
e. Medically significant (symptom atic) bradycardia 
f. Histo ry of arrhythmia  requiring an impl antable cardiac defibrillator 
g. Baseline prolongation of the rate-corrected QT interval (QTc) (e.g., repeated 
demonst ration of QTc interval >480 millis econds, or history of congenital 
long QT s yndrome, or torsades de point es) 
13. Poorly controlled diabetes mellitus  defined as glycosylated hemoglobin (HbA1 c) 
>7%; patients with a histo ry of transient glucose intoleranc e due to corticosteroid 
administra tion may be enrolled in this study if all other inclusion/ exclusion criteria 
are met 
14. Treatme nt with strong inhibitor s and/or  induc ers of cytochrome P450 (CYP) 3A4, 
CYP2C19 or  CYP2C19 within [ADDRESS_365732] dose  of study drug 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 43 
X31025 Protocol Version  4 24-January- 2020  15. Patients receivi ng systemic corticosteroids (either IV or oral steroids (doses of 
prednisone < 10mg or equivalent  are allowed ), excluding inha lers or low-dose hormone 
replacem ent therapy) within  [ADDRESS_365733] dose  of study drug 
16. Daily or chronic use of a proton pump inhibitor (PPI) and/or having taken a PPI [INVESTIGATOR_874] 
[ADDRESS_365734] dose of study drug 
11. STUDY DRUG  
11.1 Study D rug Administration 
All protocol-specific criteria for administra tion of TAK-228 + TAK-[ADDRESS_365735]  be m et and 
documented before drug administra tion. Study drug will be administered only to eligible p atients 
unde r the supe rvision of  the inve stigator. 
 
TAK- 228 + TAK-117 will be administered on an empty stom ach. It is recomm ended that 
each dose of TAK- 228 + TAK- 117 be given PO with 8 ounces  (240 mL) of w ater. Patients 
should be instructed to refrain from eatin g and drinking (except for water and prescribed 
medications)  for [ADDRESS_365736] before swallowin g. If a patient does not take their TAK- 228 + 
TAK- 117 doses within  the time frame specified (±24 hours of the QW scheduled dosing 
time, or ± 12 hours of the QD  or QD ×3days per week schedule), then the dos es will be skippe d 
and conside red missed doses. Patients will recor d any missed doses in their diary and resume  
drug administra tion at the next scheduled time with the prescribed dosage. Under no 
circumst ance will a  patient repeat a dose or doubl e-up dos es. 
 
If severe emesis or mucositis  prevents the patient from  taking scheduled doses, that dose 
will be skippe d. If emesis occur s after study medication  ingestion, the dose will not be re-
administered, and patients should resume  dosing at the next scheduled time with the p rescribed 
dosage. Patients will record the occurrence of the emesis in their dosing di aries. Unde r no 
circumst ance will a  patient repeat a dose or doubl e-up dos es. 
 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 44 
X31025 Protocol Version  4 24-January- 2020  Study drug will be administered only to eligible patients unde r the supervision of the inv estigator 
or identified sub- investigator(s). 
 
Cycles consist of  28 da ys for all treatment arms. Paclita xel will be  adminis tered on ce weekly for 
3 consecutive  weeks (on Days 1, 8, and 15 of a 28-day treatment cycle) and TAK- 228 and 
TAK-117 will be administered together, 3 days per week (on Days 2–4, 9–11, 16–18, and 23–
25 of a 28-day treatme nt cycle) in all [ADDRESS_365737] ered intravenous ly 
per its package insert or Summ ary of Produc t Characteristics (SmPC)48, 49. 
11.2 Definitions of Dose-Limiting Toxicity (DLT)  
Dose limiting toxicities  are defined according  to the AE profile observed during the first  [ADDRESS_365738] possibl y related 
to treatment with stu dy drug: 
• Any death not clearly due to underlying disease or extraneous causes  
• Hy's Law  
o Subjects with AST or ALT elevations > [ADDRESS_365739] and total bilirubin elevation >[ADDRESS_365740] without initial findings of cholestasis (elevated serum alkaline 
phosphatase)  
• Grade 3 or higher non -hematologic toxicity, despi[INVESTIGATOR_42209], except for the 
following:  
o Grade 3 hyperglycemia lasting ≤14 days (all patients should receive optimal  
antiglycemic treatment, including insulin, as clinically indicated)  
o Grade  3 rash lasting  ≤3 days (all patients  should receive topi[INVESTIGATOR_299690], 
oral antihistamines, and oral steroids, if necessary)  
o Inadequately trea ted Grade 3 nausea and/or vomiting and Grade 3 diarrhea (all 
patients should receive optimal antiemetic and/or antidiarrheal prophylaxis 
and/or treatment)  
• Patients experiencing any Grade 3 or more hematologic toxicity attributed to the 
treatme nt will hold all therapy until resolution of the toxicity to Grade 1 or baseline 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 45 
X31025 Protocol Version  4 24-January- 2020  levels.  If toxicity persists,  the p atients will be removed from  the stu dy. Upon  resolution  
of the t oxicity, the p atient will restart treatment at the original dose  at the discretion of  
the inve stigators.  No dose adjustments are allowed during the DLT phase of the study.  
• Grade 4 neutropenia lasting >7 days in the absence of growth factor support  
• Grade 4 neutropenia of any duration accompanied by [CONTACT_411] ≥38.5°C and/or  systemic 
infection  
• Grade  3 thrombocytopenia with bleeding  
• Grade 4 thrombocytopenia > 7 days  
• Any other ≥Grade 4 hematologic toxicity  
• Inability to administer at least 75% of planned doses of TAK -228 within Cycle  1, due 
to study drug- related toxicity  
• Any clinically significant occur rence that the investigator and sponsor agree would 
place patients at an undue safety risk  
 
Patients who e xperience an AE th at meets the  definition of  a DLT du ring or after compl eting 
Cycle [ADDRESS_365741] their study drug treatment interrupted. If the event resolve s to Grade 1 or 
Grade 2 for hyperglycemia or  rash or baseline values within  3 weeks of int errupting planned 
therapy, and in the opi[INVESTIGATOR_299691] t reatment outw eigh the 
risks posed by [CONTACT_299731], patients may continue  study treatment with TAK- 228 dose  
reduction. 
11.3 Dose-Modification Guidelines for all C ycles  
The primary principle for dose reduction in TAK- 228 + TAK- 117 is to maintain the 200-mg 
dose of TAK- 117, which is conside red a minima lly efficacious dose in the combina tion of TAK -
228 + TAK- 117. Thus, the dose of TAK- 228 will be reduced if necessa ry while  the dose  and 
schedule of TAK-117 is maintained when study drug administra tion is resumed (see tables 
below). 
 
If the G rade 3 or greater event that led to dose int erruption re solves to Grade 1 or baseline v alue 
within  3 weeks of interrupting  treatme nt, then the patient may resume combina tion stud y 
treatme nt if treatment with study drug is thought to be beneficial for the patient by [CONTACT_231935]’s  approval. In this case, the patient may resume  study treatme nt 
with TAK- 117 at 200 mg QD x  3 days and TAK -228 r educed b y 1 dose  level. 
 
TAK- 228 and TAK-117 should be administered in continuous  cycles, which should continue  
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 46 
X31025 Protocol Version  4 24-January- 2020  unless the  patient has a Grade 3 or greater TAK-228 a nd/or  TAK-117 re lated event. 
 
Management of neutropenia and thrombocytopenia m ay be done  at the discretion  of the 
investigators. Please s ee Appendix 5 for guidance. 
 
11.3.1  Criteria for Dose Interruption during a Cycle  
Administra tion of TAK -228 + TAK -[ADDRESS_365742] clinical  practice. The following 
non-hematologic toxicities attributed to TAK- 228 and/or  TAK-117 would not require dose 
interruption:  
• Grade  3 or higher  nausea  and/or  emesis  in the absence of optimal  anti-emetic 
prophylaxis. (Optimal anti -emetic prophylaxis is defined as an anti -emetic regimen that 
employs both a [ADDRESS_365743] schedules.)   
• Grade 3 or higher diarrhea that occurs in the absence of optimal supportive therapy  
• Grade [ADDRESS_365744] ion Schedule for TAK-228 a nd TAK-117 
Cohort TAK -228 Dose  TAK -117 Dose  TAK -228 # of  Capsules and Strength 
1 1 mg  QD x  3 100 mg  One 1 mg capsule  
2 1 mg  QD x  3 200 mg  One 1 mg capsule  
3 1 mg  QD x  3 200 mg  One 1 mg capsules 
4 2 mg  QD x  3 200 mg  Two 1 mg capsules 
5 3 mg  QD x  3 200 mg  Two 1 mg capsules 
11.3.2 Criteria for Discontinuation of Study Drugs  
In general, TAK- 228 + TAK- 117 dosing should be withh eld for ≥Grade 3 TAK- 228 and/or 
TAK- 117-related non-hematologic toxicities. If TAK- 228 + TAK-117 dosing is  delayed because 
of TAK-228 and/or TAK -117-related toxicities for > [ADDRESS_365745] clinical practice or if  >3 TAK-228 dose reductions  are required, stop 
TAK- 228 + TA K-117, discontinue  the subj ect from  the study, and compl ete the EOT  visit within  
[ADDRESS_365746] administra tion of TAK -228 + T AK-[ADDRESS_365747]. 
11.3.3 Recommended Dose Modifications for Paclitaxel Treatment Associated  
Toxicity  
Paclita xel dose modi fications may be done  at the discretion  of the investigators. Please see 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 47 
X31025 Protocol Version  4 24-January- 2020  Appendix 5 for guidance . 
12. EXCL UDE D CONCO MITANT  MEDICAT IONS  AND PROCE DURES 
Based on in vitro drug metabolism  studi es, TAK- 117 is primarily metabolized by [CONTACT_097]3A4 
(72%), with minor c ontributions  from  CYPs 1A2 (12%), 2C 9 (9%), and 2C8 (6%);  whereas, 
TAK- 228 is metabolized by [CONTACT_299732]2C19 (35%), CYP3A4 (28%), and 2C9 (28%). 
Consequently, induction of CYP3A, 2C19, and 2C9 enzymes by [CONTACT_3252]-administered  drugs can 
potentially result in decreased TAK-[ADDRESS_365748] 
dose of TAK-228 and/or TAK- 117. During the study, strong CYP3A4, CYP2C9, and 
CYP2C19 inhibito rs and clinical ly significant enzyme induc ers should onl y be administe red with 
caution a t the discretion of  the inve stigator. 
 
There is potential for TAK-[ADDRESS_365749] cancer resistance protein (BCRP ) 
subst rates (e.g., methotrexate, imatinib, topot ecan, lapatinib,  rosuva statin, etc.) and organic 
cation t ranspor ter protein 1 or 2 (OCT1 or  OCT2) subst rates (e.g., metformin, cimetidine, 
amantadine, famotidin e, pi[INVESTIGATOR_8405], etc.). If patients require treatment with medications  that are 
known subst rates of these transpor ters, then these agents should be administered with caution or 
alternative treatme nt options  should be conside red. It is recomm ended that patients requiring 
metformin for treatment of hyperglycemia resulting from TAK- 228 + TAK -[ADDRESS_365750] effective dose of metformin and ha ve their blood or serum 
glucose closely monitored. 
The following  medicatio ns and pr ocedu res are prohibit ed dur ing the study: 
• Other inve stigational agents in cluding  mTO R, PI3Kinase and A KT inhibito rs 
• Other anticancer therapi [INVESTIGATOR_299692], immunotherap y, 
radioimmunotherap y, targeted agents, radiation or surgery (subjects can have palliative 
radiation or  surgery in the  study for pre-existing  lesions  
• Systemic corticosteroids (either IV or oral steroids, excluding  inhalers), unless 
necessa ry for treatment of TAK- 228 related AE, i.e., rash or other emergent conditions 
that require intervention . Pre-medication  for paclita xel is allowed 
• Anti-epi[INVESTIGATOR_299693] 
• Concomita nt administra tion of any PPI [INVESTIGATOR_299694] d during the study. Patients 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page [ADDRESS_365751] dose of study drugs. Examples of PPIs include om eprazole, esomeprazole, 
pantopra zole, lansopra zole and ra beprazole. 
• Consumption of grapefruit or grapefruit juice is not permitte d during the study. 
Patients should not consume  food or beverages containing the  fruit or juice of 
grapefruits or Seville oranges within  [ADDRESS_365752] dose of study d rug and 
throughout the  study 
• See below restrictions  that apply to the use of CYP3A4, CYP2C19 and CYP2C9 
inhibito rs and inducer s, histamine  H2 receptor antagonists, neutralizing antacids, 
calcium a nd anti-gas preparations  
12.[ADDRESS_365753] dose of study drug. Examples of 
histamine  H2 receptor  antagonists  include ranitidin e, famotidin e, nizatidine, and cimetidine. 
 
Neutralizing antacid preparations (acid neutralizers) and calcium suppl ements are not per mitte d 
during Cycle 1 on study drug administra tion days in the phase 1/1b portion of the stu dy, but 
may be taken as neede d on non-TAK-228 + TAK-117 administra tion days. How ever, for all 
other cycles in the phase 1b portion of the study and throughout the phase 2 por tion of the study, 
administra tion of neutralizing antacids and calcium preparations  is permitte d except from 4 hours 
before until  2 hours after TAK-228 + TAK-[ADDRESS_365754] antacid properties, and should also not be  permitte d from 4 hour s before until 
2 hours after study drug administra tion. 
 
Strong CYP3A4 and CYP2C19 inducer s and/or inhibito rs and mode rate inhibito rs of CYP2C9 
should only be administered with cauti on, at the discretion of the investigator. Alt ernative 
treatme nts, if  available, should be  considered.  
 
Prophylactic use of antiemetic, anti -nausea, and antidiarrheal medications is encouraged and 
may be used before each TAK -228 and TAK -117 dosing as needed throughout the study.  
 
Other medications  considered necessary for the safety and well-being of the patient may be 
administered a t the discretion of  the inve stigator. 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page [ADDRESS_365755] received live vaccines 
should be avoide d during treatme nt with study  drug. Examples of live vaccines are: intranasal 
influenza, measles, mumps, rubella, oral polio, Bacille Calmette-Guerin (BCG), yellow fever, 
varicella and TY21a  typhoid vacci nes. 
 
No dietary restrictions  will be impos ed on study patients other than avoiding food or beverages 
containing the fruit or juice of grapefruits or Seville oranges within [ADDRESS_365756] 20 ounces  of fluids  a day, especially on days 
requiring fasting (per protocol), with administra tion of IV fluids  in the clinic as indicated to avoid 
dehydration. 
 
Pregnancy 
It is not known  what effects TAK-228 + TAK- [ADDRESS_365757] dose of study drug, as specified below. 
• Women must m eet 1 of  the followin g: 
o Postm enopa usal for at least 1 year before the screening visit, OR  
o Surgically sterile, OR 
o If they are of childbe aring potential, agree to practice 21 highly effective  method 
of contraception and 1 additiona l effective (barrier) method, at the s ame time, 
from  the time  of signing the informed consent through 90 days (or longer, as 
mandated by [CONTACT_299728] [e.g., USPI, SmPC, etc.;]) after the last dose  of study 
drug, OR 
o Agree to practice true abstin ence, when this is in line with the prefer red and 
usual life style of the patient. (Periodic  abstin ence [e.g., calendar, ovulation, 
sympto - thermal and post ovulation methods ], withd rawal, spermicides only 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 50 
X31025 Protocol Version  4 24-January- 2020  and lactational amenorrhe a are not  acceptable m ethods  of contraception. Female 
and m ale condoms should not be  used tog ether.) 
• Male patients, even if surgically sterilized (i.e., status post va sectomy), 
who: 
o Agree  to practice highly  effective  barrier  contraception  during  the entire  study 
treatment period and through [ADDRESS_365758] dose of study drug, OR  
o Agree to pr actice true a bstinence, when this is in line with the preferred and 
usual lifestyle of the patient. ( Periodic abstinence [e.g.,  calend ar, ovulation, 
sympto - thermal, post ovulation methods for  the female partner], withdrawal, 
spermicides only, and lactational  amenorrh ea are not acceptable  methods  of 
contraception. Fema le and male condoms should not be used together.)  
o Agree not to donate sperm during the course of this study or [ADDRESS_365759] dose of study drug  
12.3 Managemen t of Clinical Events/Dose Modifications  
12.3.1 Management of Hyperglycemia  
In normoglycemic patients (no previously diagnosed diabetes mellitus, FBG and HbA1c within 
normal limits at screening), FBG should be checked at the clinic visits, every two weeks during the 
first cycle  of treatment then day 1 of each subsequent cycle . In addition, HbA1c will be measured 
every 3 cycles .  
 
In patients with prediabetes (FPG 100- 125 mg/dL, 2- h plasma glucose 140- 199 mg/dL, HbA1c 5.7-
6.4% at screening), in addition to obtaining fasting serum glucose levels at the clinic visits as 
outlined in the SCHEDULE OF EVENTS, patients randomized to receive TAK -228 will be 
provided with a glucometer and trained in its use to monitor their daily predose fasting blood glucose 
levels at home. The level should be collected daily, predose on dosing days, and at approximately 
the same time each day. Patients will be instructed to notify the study staff of any abnormal 
readings  ≥150  mg/dL and <160 mg/dL at the next office visit. Patients will be instructed to notify 
the study staff immediately with any reading > 16 0 mg/dL for further instructions on the 
management of their hyperglycemia. Hyperglycemia observed during home glucose monitoring 
should be confirmed in the clinic. Investigators will be responsible for reviewing the home glucose 
monitoring logs for hypergl ycemia. If no irregularities in the F PG level are observed during a 
minimum of 2  consecutive cycles, then the frequency of in -home FBG testing can be reduced to a 
minimum frequency of once weekly (day 4, 11, 18, and 25) depending on the investigator’s 
judgment and approval. Patients will continue to notify the investigator of FBG levels  ≥150 mg/dL, 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 51 
X31025 Protocol Version  4 24-January- 2020  and if blood glucose levels are not well controlled, or if they require either oral hypoglycemic agents 
or insulin to control blood glucose levels, then the frequency of in- home testing of FBG levels will 
be reinstated to daily and hyperglycemia is managed aggressively as described in Table below.  
For the patients with pre -existing  diabetes  or patients with a HbA1c >7, self -monitoring should be 
intensified. It is recommended to initiate a treatment with  metformin , the first -line drug for 
management of hyperglycemia, when FBG is above 160 mg/dL, when 2- h plasma glucose is above 
200 mg/dl at any time or when HbA1c is above 6.5%. To aggressively manage the hyperglycemia 
per standard clinical practice, the guidelines  are provided to aid the investigator in initiating 
antiglycemic therapi[INVESTIGATOR_014].  
 
For the patients with known  diabetes  mellitus , it is recommended to initiate a treatment 
with metformin , the first -line drug for management of hyperglycemia, when FBG is above 
126 mg/dl (7.0  mmol/l), when plasma glucose i s above 200 mg/dl at any time or when HbA1c is 
above 6.5%.  
 
On the basis of the clinical experience in TAK -[ADDRESS_365760] their glucose closel y monitored by [CONTACT_464]. The 
investigator may choose either to continue close monitoring of patients who develop Grade 1 
hyperglycemia (FBG >ULN ≤160  mg/dL) or consider initiating treatment with an oral 
hypoglycemic agent, such as metformin. All patient s with ≥ Grade 2 hyperglycemia (FBG 
>160 mg/dL) should be treated aggressively with oral hypoglycemic agents and/or insulin as 
clinically indicated while continuing on TAK -[ADDRESS_365761] -acting insulin sensitizer, such as 
metformin at 500 mg orally daily, and titrate up to a maximum of 1000 mg orally twice daily as 
needed. Concurrent addition to metformin of dipeptidyl peptidase -4 inhibitors (eg, sitagliptin or 
vildagliptin) and/or insulin should also be considered. Oral sulfonylureas (eg, glipi[INVESTIGATOR_53289]) 
should be used with caution due to the higher risk of inducing hypoglycemia in patients. The dose 
of oral hypoglycemic agents should be adjusted in patients with renal insufficiency. In addition, 
patients should be encouraged to follow a low -carbohydrate diet once hyperglycemia is first 
observed.  
Guid ance on study drug dose modi fication  for patients with hyperglycemia  is provide d in the  
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 52 
X31025 Protocol Version  4 24-January- 2020  table below: 
 
Table: Management of Hyperglycemia 
Grade Description Treatment Dose Modification 
1 Fasting blood 
glucose: FBG  >ULN 
to 160 mg/dL • Continue close monitoring of blood 
sugar. 
• Initiate  oral hypoglycemic agent. None 
2 FBG  >160  to  250 
mg/dL • Initiate  oral hypoglycemic agent and/or 
insulin if not well controlled on oral 
agent. None 
≥3 FBG >250 mg/dL • Initiate  oral hypoglycemic agent 
and/or insulin. Hold TAK-228 and TAK-117 
until ≤Grade 2. 
Resume TAK-228 and TAK-117 
based on timing of reco very 
after maximal treatment: 
• ≤1 week: resume TAK-228 
and TAK-117 at  same dose 
and schedule. 
• >1 but ≤2 weeks: reduce TAK-
228 by 1 dose level and resume 
TAK -117 at same dose and 
schedule  
• >2 weeks: discontinue patient 
from the study. 
Prevention/Prophylaxis: 
• Follow fasting glucose levels during clinic visits. 
• Monitor home glucometer test results. 
• Check HbA1c levels every 3 cycles  during therapy. 
• Recomme nd life-style modificatio ns, as appropr iate (balanced diet, limited alcohol consumption, increased 
phys ical activity). 
• Most epi[INVESTIGATOR_13368] [ADDRESS_365762] therapeutic dose is recomme nded to prevent higher grade hyperglycemia. 
• Fasting blood glucose levels ≥150 mg/dL by [CONTACT_299733]. 
HbA1c=glycosylated  hemoglobin, ULN=upper limit of normal. 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 53 
X31025 Protocol Version  4 24-January- 2020  12.3.2 Management of Hyperlipi[INVESTIGATOR_299695] d 
below. 
Table: Management of Hyperlipi[INVESTIGATOR_299696] 
1 Cholesterol >ULN to 300 mg/dL 
OR 
Triglycerides >150 to 300 mg/dL None None 
2 Cholesterol >300 to 400 mg/dL 
OR 
 
Triglycerides >300 –500 mg/dL Treat hyperlipid emia according 
to standard  guidelin es. 
Triglycerides ≥500 mg/dL should 
be treated  urgently, due to risk 
of pancreatitis. Maintain  dose,  if tolerable.  
 
If toxicity becomes intolerable, 
interrupt TAK -228 and TAK -
117 until recovery to ≤Grade 
1. Re -initiate TAK -228 
+TAK-117 at the same dose 
level 
3 Cholesterol >400–500 mg/dL 
OR 
Triglycerides >500– 1000 mg/dL Same as for Grade 2 Hold TAK-228 a nd TAK - 117 
until recovery to ≤Grade 1, then 
reinitiate TAK-228 at a dose 
reduced by 1 level and resume 
TAK -117 at same dose and 
schedule  
 
4 Cholesterol >500 mg/dL 
OR 
Triglycerides >1000  mg/dL Same as for Grade 2 Same as for Grade 3. 
Prevention/Prophylaxis:  
Life-style modification s, as a ppropr iate (balanced diet, li mit alc ohol consumption, increase phys ical activ ity) 
ULN=upper limit ofnormal. 
 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 54 
X31025 Protocol Version  4 24-January- 2020  12.3.3 Management of Oral Mucositis  
Guid ance on stud y dose modi fication f or patients with o ral mucositis is p rovided below. 
Table: Management of Oral Mucositis 
Grade Description Treatment Dose Modification 
1 Asymptomatic or mild 
symptoms. Nonalcoholic mouthwash, or 
0.9% salt water rinse. 
Consider topi[INVESTIGATOR_231907]. None 
2 Mod erate pain,not interfering 
with oral in take. Mod ified 
diet indicate d. Topi[INVESTIGATOR_032]. 
Topi[INVESTIGATOR_11930]. 
Initiate  antiviral or antifungal 
therapy, if indicate d. Maintain TAK-228 and TAK-
117 dose if tolerable 
Hold only TAK-228 and 
TAK-117 if  intolerable 
until recovery to ≤Grade 
1, then restart at same 
dose. 
3 Severe pain, interfering with 
oral intake. Same as for Grade 2. 
Consider intralesional corticosteroids. Hold all drugs  until recovery to 
≤Grade 1, then restart TAK -
228 at a dose reduced by 1 
level and resume TAK -117 at 
same dose and schedule  
 
4 Life-threatening 
consequences. Same as for Grade 2 
Consider intra-lesional corticosteroids Stop all drugs a nd discontinue 
patient from the study 
Prevention/Prophylaxis: 
• Initiatio n of a nonalcoholic mouth wash, or 0.9% salt water rinses 4–6 times daily is strongly recomme nded at 
the start of therapy before signs of mucositis develop. 
• Avoid using agents containing hydrogen peroxide, iodine, and thyme derivatives in management of 
stomatitis, as they may worsen mouth ulcers. 
 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 55 
X31025 Protocol Version  4 24-January- 2020  12.3.4 Management of Rash  
Guid ance on stud y drug dose  modi fication f or patients with ra sh is p rovided below. 
Table: Management of Rash  
Grade Description Treatment Dose Modification 
≤2 Macules/papules covering 
≤30% body surface area 
with or without symptoms. Consider treatment with topi[INVESTIGATOR_190461]/ointment and/or 
oral anti-histamines or antibiotics. None 
3 Macules/papules covering 
>30% body surface area 
with or without symptoms. Consider treatment with topi[INVESTIGATOR_190461]/ointment, oral anti-
histamines, oral antibiotics, 
and/or pulsed steroids. Hold  TAK-228  and  TAK-117 
until ≤Grade 2 
 
Resume TAK-228 and TAK-117 
based on timing of recovery: 
• ≤3 weeks: reduce TAK-228 b y 1 
dose level and resume TAK -117 
at same dose and schedule  
• >3 weeks: stop TAK-228 and 
TAK-117 a nd discontinue patient 
from the study 
4 Rash acneiform/ 
papulopustular with 
papules  and/or pus tules 
covering any % body 
surface area, which may 
or may  not  be asso ciated  
with symptoms of pruritus 
or tenderness, and are 
associated  with extensive  
superinfection with 
intravenous (IV) a ntibiotics 
indicate d; life threatening 
consequences (NCI 
CTCAE Version 4.03,  
effective date 14 June 
2010) .  Permanently discontinue study 
treatment, unless they derive 
clinical benefit, in which case they 
may be retreated  at a reduced dose 
level after recover to ≤Grade 1 
severity 
Prevention/Prophylaxis: 
• Rash should be managed aggressively. The investigator should consider consulting a dermatologist or other 
speciali st, if needed. 
• A skin biopsy at the site of rash should be considered as soon as possi ble after the initial epi[INVESTIGATOR_299697].  
 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 56 
X31025 Protocol Version  4 24-January- 2020  12.3.5 Management of Nausea/Vomiting  
Guid ance for patients wi th nausea and/or vomiting is p rovide d in the  table below. 
Table Management of Nausea/Vo miting 
Grade Description Treatment Dose Modification 
≤2 Loss of  appetite  with  or 
without decreased oral intake; 
1–5 epi[INVESTIGATOR_299698] 24 hours. Maximize anti-emetic t herapy. 
Consider IV fluid hydration. None 
≥3 Inadequate oral intake; 
≥6 epi[INVESTIGATOR_299698] 24 hours. Maximize anti-emetic t herapy. 
Initiate  tube feeding, IVF or 
TPN. If experienced for ≤ 72 hours, 
hold TAK-228 a nd TAK-117 
until ≤ Grade 1, then resume 
TAK-228 and TAK-117 without 
dose modificatio n.  
 
If experienced for >72 hours 
despi[INVESTIGATOR_11920], hold 
TAK-228 and TAK-117 until ≤ 
Grade 1, then resume treatment 
with the dose of TAK-228  
reduced by 1 level and resume 
TAK -117 at same dose and 
schedule.  
 
Prevention/Prophylaxis: 
Prophylactic  use of antiemetic, anti-nausea, and antidiarrheal medicatio ns is encouraged and may be used 
before each TAK-228 and TAK -117 dosing as needed throughout the study. 
IV=intravenous, IVF=intravenous fluids, TPN=total parental nutrition. 
 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page [ADDRESS_365763] ion 
Guid ance for TAK- 228 and TAK-117 dose adjustments for patients with left ventricular 
dysfunction is p rovide d below. 
 
Table: Management of Left Ventricular Dysfunction 
Grade Description Dose Modification 
1 Asymptomatic decline in:  
LVEF >15% from baseline values, OR  
LVEF >10% to 15% from baseline values and is 
below institution’s LLN  No change; continue TAK-228 and TAK-117 at 
the same dose and schedule 
≥2 Symptomatic cardiac dysfunction/congestive 
heart failure. Discontinue treatment. 
LLN=lower limit of normal, LVEF=left ventricular ejection fraction 
 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 58 
X31025 Protocol Version  4 24-January- 2020  12.3.7 Management of Patients with QTc Prolongation  
Guid ance for TAK-228 and TAK- 117 dose adjustm ents for patients exhibiting  a prolonged 
QTc interval is p rovide d below. 
Table Management of QTc Prolongation 
Grade Description Treatment Dose Modification 
2 480 msec <QTc 
<501 msec Evaluate for other possible causes (e.g., 
elect rolyte disturbance, co ncomitant 
medicatio n, etc.). None; continue TAK-228 and TAK-117 at 
the same dose and schedule. 
≥3 QTc ≥501 msec Evaluate for other possible causes (e.g., 
elect rolyte disturbance, co ncomitant 
medicatio n); Consider a formal consult by 
a card iologist; Notify the study doctor; 
Additional ECGs may be performed at 
intervals that the treating physician deems 
clinically appropr iate until repeated  QTc 
measurements fall or are below the 
threshold interval that triggered the repeat 
measurement. Hold all drugs  
 
The decision whether to reinitiate TAK- 
 228 and TAK-117 with or without dose 
reduction and additio nal monitoring in 
those patients who had asymptomatic 
prolonged  QTc ≥501 msec (Grade 3) that 
has  reverted  to  an  accep table interval, 
have previously tolerated TAK-[ADDRESS_365764] benefitted 
from treatment with eith er disease control 
or respons e, will be agreed to by [CONTACT_163553] a cas e-by-case basis 
 
Patients who experience persistent 
symptomatic Grade 3 or Grade 4 QTc 
prolongatio n without another cause should 
permanently discontinue study treatment. 
ECG=elect rocardiogram, IV=intravenous, msec=milliseconds, QTc=QT interval corrected  for heart rate. 
(a) A list of medicatio ns known to prolong QTc can be found at https://www.crediblemeds.org/new-drug-list/ 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 59 
X31025 Protocol Version  4 24-January- 2020  12.3.8 Management of Asthenia, Weakness and Fatigue  
Guid ance on dose adjustment for patients with other non-hematologic toxicities is provide d 
below. 
Table Management of Asthenia, W eakness, and Fatigue 
Grade Description Treatment Dose Modification 
1 Mild; asymptomatic or mild 
symptoms; cli nical or 
diagnostic observations only; 
intervention not indicate d. Initiate  appropr iate medical 
therapy and monitor. If tolerable, then no adjustment is 
required. 
2 Mod erate; minimal, local or 
noninvasive intervention 
indicate d. Initiate  appropr iate medical 
therapy and monitor. If tolerable, no adjustment required. 
If toxicity becomes intolerable, 
hold TAK-228 and TAK-117 
until recovery to ≤Grade 1, then 
reinitiate  at same dose. 
≥ 3 Severe or medically significant 
but not imme diately life-
threaten ing; ho spi[INVESTIGATOR_5186] n or 
prolongatio n of hospi[INVESTIGATOR_5186] n 
indicated  Hold all drugs  until recovery to ≤ 
Grade 1. Reinitiate TAK-228 at 
dose reduced by 1 level and 
resume TAK -117 at same dose 
and schedule.  
 
Patients who develop Grade 4 n on-
hematological to xicities (with the 
exception of isolated  non- 
clinically significant laboratory 
values) should permanently 
discontinue study treatment, 
unless they derive clinical 
benefit, in  which case they may 
be retreated at  a reduced dose 
       
 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 60 
X31025 Protocol Version  4 24-January- 2020  12.3.9 Management  of Asparte  Aminotransferase/Alanine  Aminotransferase  
Elevations  
Guid ance on dos e adjustm ent for patients with A ST/ALT elevations is p rovide d below. 
Table Management of Aspartate Aminotransferase/Alanine Aminotransferase 
Elevations 
Grade Description Treatment Dose Modification 
1 >ULN to 3×ULN None None 
2 Asymptomatic with levels 3 to 
5×ULN; >3×ULN with the 
appear ance of worsening 
fatigue, nausea, vomiting, right 
upper quadrant pain or 
tenderness, fever, rash, or 
eosinophilia. Closely monitor LFTs at lea st 
weekly or more frequently as 
indicate d. 
Assess patient for other caus es of 
transaminitis (e.g., past 
medical history, concomitant 
medicatio ns). None 
3 >5 to 2 0×ULN; >5×ULN for 
>2 weeks Same as for Grade 2. Hold paclitaxel, TAK-228 and 
TAK-117 until ≤ Grade 1; 
Restart all drugs at  the same 
dose. Permanently discontinue 
study treatment if in 
combination with Grade 2 
total bilirubin ele vation when 
alternative ca uses cannot be 
identified (i.e., Hy’s Law); 
4 >20×ULN Same as for Grade 2. Stop paclitaxel, TAK-228 and 
TAK-117 a nd discontinue 
patient from the s tudy. 
Permanently discontinue study 
treatment if in c ombination 
with Grade 2 total bilirubin 
elevation when alte rnative 
causes cannot be identified (i.e., 
Hy’s Law). 
Prevention/Prophylaxis: 
Ensure proper  screening of patients for study participation. 
LFTs=liver function tests, ULN=upper limit of normal. 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 61 
X31025 Protocol Version  4 24-January- 2020  12.3.10 Management of Non -infectious Pneumonitis  
Guid ance for the management of pneumonitis is p rovide d below. 
Table Management of Non-infectious Pneumonitis 
 
Grade  
Description  
Treatment TAK-228 Dose 
Modification 
1 Asymptomatic: Radiographic findings 
only. Rule out infection and 
closely monitor. None 
2 Symptomatic: 
Not interfering with activities of daily 
living. Rule out infection a nd 
consider treatme nt with 
cortico steroids until 
symptoms impro ve to 
≤Grade 1.  Hold TAK-228 and TAK-
117 
When symptoms ≤Grade 1, 
reinitiate  TAK-228 at a 
dose reduced by 1 level 
and resume TAK -117 at 
same dose and schedule.  
 If no recovery within 4 
weeks, then discontinue 
TAK -228 and TAK -117 
3 Symptomatic: 
 Interfering with activities of daily 
living;  
 Requires administration of oxygen.  Rule out infection a nd 
consider treatme nt with 
cortico steroids until 
symptoms impro ve to 
≤Grade 1.  Hold all drugs until 
symptoms resolve to 
≤Grade 1.  
Consider reinitiating TAK -
228 at a dose reduced by 
1 level  and resume TAK -
117 at same dose and 
schedule  
 
If toxicity recurs at Grade 
3, discontinue TAK -228 
and TAK -117 
4 Life-threatening: 
 Ventilatory support indicated  Rule out infection a nd 
consider treatme nt with 
corticosteroids  Discontinue all drugs . 
12.4 Description of Investigational Ag ents 
TAK- 228 will be suppli ed as capsul es for oral administra tion. The study drug is available in 3 
dose strengths, 1 mg, 3 mg, and 5 mg, each containing 1 mg, 3 mg, and 5 mg of  TAK-228, 
respectiv ely, in addition to the following in active ingredients: microcrystalline cellulose (solid  
filler/diluents), magnesium  stearate (lubricant), and hard gelatin capsule. All [ADDRESS_365765] rengths are 
formulated into size 2 capsul es, and each dose strength is differentiated by [CONTACT_68458], as listed 
below: 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 62 
X31025 Protocol Version  4 24-January- 2020  • TAK- 228 c apsules, 1 mg -  white  opaque color 
• TAK- 228 c apsules, 3 mg – ora nge opaque color; and/or  
• TAK- 228 c apsules, 5 mg – g rey opaque color 
TAK- 117 will be suppli ed as 100 mg capsule s for oral administra tion. Each 100 mg capsule 
contains 100 mg of MLN1117 and the following inactive  ingredients: hard gelatin capsule and 
small amount of  colloid al silic on di oxide. 
 
Refer to  the MLN0128 (TAK- 228), MLN1117 (TAK- 117), and MLN0128  + MLN1117 (TAK -
228 +  TAK- 117) IBs for full details. 
12.5 Prep aration, Reconstitutio n, and Dispensing 
TAK -228 and T AK-117 
TAK- 228 and TAK-117 study drugs will be provided in labeled bottles in accor dance with all 
applicable  regulations. Materials provide d by [CONTACT_299734]. 
 
TAK- 228 and TAK-117 are anticancer drugs and, as with other potentially toxic compounds, 
caution should be  exercised wh en handling  TAK- 228 and TA K-117 capsul es. 
 
Paclitaxel 
Paclita xel will be dilut ed prior to infusion in 0.9% Sodium  Chloride for Injection, USP; 5% 
Dextrose Injection, USP; 5% Dextrose and 0.9% Sodium  Chloride Injection, USP; or 5% 
Dextrose in  Ringer’s Injection  to a final concen tration of 0.3 to 1.2m g/mL. At ambient 
temperatu re (approximately 25°C  /77°F) and room lighting  conditions  the solution is physically 
and chemically stable for up to [ADDRESS_365766] will be prepared and stored in glass, polypropylene, or polyolefin containers; 
DEHP -containing (polyvinyl chloride (PCV)) containers should not be  used. 
 
Paclita xel will be administ ered using a vented Paclitaxel set with in-line 0.22- micron filter and 
run ove r at least  1 hou r. 
 
All patients should be p re-medicated prior to  paclita xel infusion with corticosteroids, 
diphe nhydramine, and H 2 antagonists, in or der to prevent severe hypersensitivity reactions.  
 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page [ADDRESS_365767] sto re acco rding to the  labeled conditions. 
 
TAK- 228 and TAK-117 will be provide d in high density polyethylene (HDPE) bottles with 
polypropylene, child-resistant caps and induc tion s eal. TAK- 228 will contain 30 capsules per 
bottle. TAK -117 will contain 14 capsules per bottle. 
 
TAK- 228 and TAK-117 are packaged and labeled in accordance with all applicable regulations. 
12.7 Storage, Handlin g, an d Account ability 
Upon receipt  at the investigative site, drug shoul d be stored in the original bottles until use and 
stored at room temperatu re from 15°C  to 30°C  (59°F  to 86°F ). All te mperature excursions  will 
be reported for assessment and author ization for continue d use. All inv estigational suppli es must  
be sto red in a secure area with controlled access and will be sto red in or iginal packaging. All 
drug suppli es should be  used bef ore the retest expi[INVESTIGATOR_5695]. 
 
Because TAK-[ADDRESS_365768] with the p owder (e.g., from  a broken capsul e), the 
skin should be washed imme diately with soap and copi[INVESTIGATOR_299699] [ADDRESS_365769] 15 minut es. Medical p ersonne l should be  notified. 
 
Patients will receive  instructions  for home  storage and administra tion of TAK- 228 and 
TAK- 117. 
 
Account ability for TAK-228 a nd TAK- 117 at all stu dy sites is the responsibili ty of the sponsor -
investigator. 
 
Comm ercial paclita xel will be sto red per institution al guidelines.  Unope ned vials of paclitaxel 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 64 
X31025 Protocol Version  4 24-January- 2020  are stable until  the d ate indicated on the packa ge w hen stored between 20 to 25°C (68 to 77°F) , 
and protected from lig ht.  
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 65 
X31025 Protocol Version  4 24-January- 2020  12.8 Study Co mpliance 
Study drug will be administered or dispensed only t o eligible patients under the supervision of 
the investigator or identified sub -investigator(s). The appropriate study pe rsonnel will maintain 
records of study drug re ceipt and dispensing.  
12.9 Term ination of Treatmen t and/or  Study P articipation 
Patients will be informed that they have the right to withdraw from the study at any time for 
any reason, without prejudice to their medical care. The investigator also has the right to 
withdraw patients from the stu dy for any of the following r easons:  
• Adverse event 
• Protocol viol ation 
• Lost to f ollow -up 
• Progressive  disease 
• Study terminated 
• Other 
Patients who are withdr awn from the study will not be repla ced. At the time of withdrawal, all 
study procedures outlined for the End of S tudy visit should be completed. The primary reason 
for patient’s withdrawal from the study shou ld be recorded in the source documents and CR F. 
 
13.  Dose Expansion 
After completion of the DLT phase, the projected phase [ADDRESS_365770] cycle, including GCSF. 
Further, all patients will receive modified blood glucose monitoring and be strati sfied based 
upon their history of hyperglycemia and respons e to therapy.  
14. STATISTICAL  AND QUANT ITATIVE ANAL YSES 
14.1 Statistical Meth ods 
The demographic and clinical char acteristics of the study patients will be summariz ed using 
descriptive statistics  
• Primary objectiv e: The maximum tolerable  dose (MTD)  will be assessed, which is 
the dose  level at whi ch < one-third of patients will experience a dose-limiting  toxicity 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 66 
X31025 Protocol Version  4 24-January- 2020  (DLT) 
• Seconda ry objectives: 
1. Adverse events will be defined according to the CTCAE v. 4.[ADDRESS_365771] 1.1 response  
criteria. Numb er and type of responses will be  summ arized with de scriptive  
statistic s 
• Explora tory objectiv es 
1. Response  rate and re lationship with  genomic  alterations  will be  examin ed by 
[CONTACT_2329]  a two-sided Fisher Exact te st due  to the  small sample  sizes 
2. TRSC and H RQOL -LASA scores will be  summ arized with de scriptive  statistic s 
15. ADVE RSE EVENTS 
15.1 Definitions 
15.1.1 Adverse Event Definition  
Adverse event (AE) means any untow ard medical occurrence in a patient or subject 
administered a medicinal produc t; the untow ard medical occurrence does not necessarily 
have a causal relationship with this treatment. An AE can therefore be any unfavorable and 
unint ended sign (including an abnormal laboratory finding ), symptom,  or disease tempora lly 
associated with the use o f a medicinal (investigational) produc t whether or not it is related to the  
medicinal produc t. This includes any newly occurring event, or a previous condition that has 
increased in s everity or frequency since the administra tion of  study drug. 
 
An abnormal laboratory value will not be assessed as an AE unless that value leads to 
discontinua tion or delay in treatme nt, dose modification,  therapeutic intervention, or is 
considered b y the investigator to be a clinically significant change from ba seline. 
15.1.2 Adverse Drug Reaction  
Adverse event (AE) means any untow ard medical occurre nce in a patient or subject administered  
a medicinal produc t; the untow ard medical occurrence does not necess arily have a causal 
relationship with this treatme nt. An AE can therefore be any unfavorable and unint ended sign 
(including a n abnormal laboratory finding ), symptom,  or disease tempora lly associated with  the 
use of a medicinal (investigational) product whether or not it is related to the  medicinal produc t. 
This includes any newly occurri ng event, or a previous condition that has increas ed in s everity 
or frequency since the administra tion of  study drug . 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 67 
X31025 Protocol Version  4 24-January- 2020   
An abnormal laboratory value will not be assessed as an AE unless that value leads  to 
discontinua tion or delay in treatme nt, dose modification, therapeutic  intervention, or is 
considered b y the investigator to be a clinica lly significant change from ba seline. 
15.1.3 Serious Adverse Event Definition  
Serious AE ( SAE) means any untoward medical occurrence that at any dose: 
• Results in d eath 
• Is life-threatening (refers to an AE in which the patient was at risk of death at the 
time of the event. It does not refer to an event which hypothe tically might have 
caused death if it were more severe). 
• Requires inpatient hospi[INVESTIGATOR_1324] 
(see clarification in the  paragraph be low on pl anned hospit alizations ). 
• Results in persiste nt or significant disability or incapacity. (Disability is defined 
as a subst antial disruption of  a person’s ability to conduc t normal life functions). 
• Is a congenital an omaly/birth defect 
• Is a medically important event. This refers to an AE that may not result in death, be 
imme diately life threatening, or require hospi [INVESTIGATOR_059], but  may be consid ered s erious 
when, based on appropriate medical judgment, may jeopardize the patient, require 
medical or surgical intervention to  prevent 1 of the ou tcomes liste d above , or involve s 
suspected transmission  via a m edicinal produc t of an infectious  agent. Examples of 
such medical events include allergic bronchospa sm requiring intensive t reatme nt in an 
emergency room or at home, blood dyscrasi as or convulsions  that do not  result in 
inpatient hospit alization, or the developm ent of drug dependency or drug abuse; 
any organism,  virus, or infectious  particle (e.g., prion protein transmitting 
Transmissible  Spong iform Encepha lopathy), pathogenic or nonpa thogenic, is 
considered a n infectious agent. 
Clarification  should be made between a serious AE (SAE ) and an AE that is considered s evere 
in intensity (Grade 3 or 4), because  the terms serious and severe are NOT synony mous. The 
general term severe is often used to describe the intensity (severity) of a specific event;  the event 
itself, however, may be of relatively minor  medical significance (such as a Grade 3 head ache) . 
This is NOT  the same as serious , which is based on pa tient/event outcome or action  criteria 
described above , and is usually associated with events that pose a threat to a patient’s life or 
ability to function. A severe AE (Grade 3 or 4) do es not necessar ily need to be considered serious. 
For exampl e, a white  blood cell count of 1000/mm 3 to less than 2000  is considered Grade 3 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 68 
X31025 Protocol Version  4 24-January- 2020  (severe)  but may not be considered serious. Seriousne ss (not intensity) serves  as a guide for 
defining regulatory reporting obli gations. 
15.2 Procedures f or Rep ortin g Serio us Adverse  Events 
Adverse Events may be spontaneously identified by [CONTACT_5363]/or in response to an open 
question from study personnel or revealed by [CONTACT_4171], physical examination, or other 
diagnostic procedures. Any clinically relevant deterioration in laboratory assessments  or other 
clinical finding is considered an AE. When possible, signs and symptoms indicating a common 
underlying pathology should be noted as one comprehensive event.  
 
Adverse Events which are serious must be reported to [COMPANY_005] Pharmacovigilance (or designee) 
from the time of consent up to and including [ADDRESS_365772] dose of 
TAK- 228. Any SAE that occurs at any time after completion of TAK -228 treatment or after the 
designated follow -up period that the sponsor -investigator and/or sub-  investigator considers to 
be related to any study drug must be repor ted to [COMPANY_005] Pharmacovigilance (or designee). In 
addition, new primary malignancies that occur during the follow -up period (up to 24 months)  
must be reported.  All new cases of primary malignancy must be reported to [COMPANY_005] 
Pharmacovigilance (or designee).  
 
Planned hospi[INVESTIGATOR_299700] (e.g., surgery w as performed earlier or later than 
planned). All SAEs should be monitored until they are resolved or are clearly determined to be 
due to a patient’s stable or chronic condition or intercurrent illness (es).  
 
Since this is an investigator -initiated study, the principal investigator [INVESTIGATOR_124]. Casey Williams , also 
referred  to as the sponsor -investigator,  is responsible  for reporting  serious adverse events (SAEs) 
to any regulatory agency , data safety board,  or IRB.  
 
Fatal and Life Threate ning SAEs within  24 hours of the sponsor -investigator’s 
observation or  awareness of the event 
 
All other serious (non-fatal/non life threatening) events within  4 calendar days of 
the sponsor -investigator’s obs ervation or  awareness of the event 
 
 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 69 
X31025 Protocol Version  4 24-January- 2020  The sponsor -investigator  or designee will send all SAE reports to [COMPANY_005] Pharmacovigilance 
(or designee) within [ADDRESS_365773] include at minimum:  
• Event term(s) 
• Serious criteria  
• Intensity of the event(s): Sponsor -investigator’s or sub-investigator’s determination. 
Intensity for each SAE, including  any lab abnormalities, will be determined by [CONTACT_299735], as a guideline, whenever possibl e. 
The c riteria are available online at http://c tep.can cer.gov/reporting/ctc.html.  
• Causality of the event(s): Sponsor -investigator’s or sub-investigator’s determination 
of the relationship of  the event(s) to study drug administra tion 
Follow -up information on the SAE may be requested by [CONTACT_299736] (or 
designee).  
 
In the event  that this is a multisite  study, the sponsor -investigator is responsible  to ensure that 
the SAE reports are sent to [COMPANY_005] Pharmacovig ilance (or designee ) from  all sites participating 
in the study. Sub-investigators must  report all SAEs to the sponsor -investigator so  that the 
sponsor -investigator can meet his/her foregoing reporting obligations  to the required regulatory 
agenc ies and to [COMPANY_005] Pharmacovig ilance, unless other wise agreed between the  spons or-
investigator and sub- investigator(s). 
 
Relationship to  all stu dy drugs for each S AE will be determined by [CONTACT_299737]-  
investigator by [CONTACT_299738]:  Is there a reason able possibilit y that the 
AE is associated with the study drug(s)?  
 US and Canada 
Toll-Free Fax #: [PHONE_323] 
E-mail: [EMAIL_039] 
 
All o ther countr ies (Rest of Wor ld) 
Fax #: [PHONE_6227]  
E-mail: [EMAIL_039] 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 70 
X31025 Protocol Version  4 24-January- 2020  Suggested Reporting F orm: 
• SAE R eport Form (a sample will be  provide d) 
• US FDA  MedWatch  3500A:  
http://www.fda.gov/Safety/MedWatch/HowToReport/DownloadForms/default.htm  
• Any other form deemed appropriate by [CONTACT_456] -investigator 
15.[ADDRESS_365774] eted Pregnancy Form to the [COMPANY_005] Pharmacovi gilance 
or designee imme diately (see Section  8.2). The pregnancy must  be follow ed for the final 
pregnancy out come (i.e., delivery, still birth, miscarriage) and [COMPANY_005] Pharmacovi gilance or 
designee will re quest this in formation from the  spon sor-investigator. 
 
If a female partner of a male patient becomes pregnant during the male patient’s participation in 
this study, the sponsor -investigator must  also imme diately fax a compl eted Pregnancy Form to 
the [COMPANY_005] Pharmacovi gilance or designee (see Section 8.2). Every effor t should be  made 
to follow the  pregnancy for the final pregnancy outcome. 
 
Suggested Pregnancy Reporting F orm: 
Pregnancy Report Form (a sample  will be  provide d) 
16. ADM INISTRAT IVE REQUIREME NTS 
16.[ADDRESS_365775] [COMPANY_005] (see 
below) and re port the event. W henever possibl e, the associated produc t should be m aintained in 
accor dance with the label instructions  pending  further guidance from  a [COMPANY_005] Quality 
representative. 
 
A medication  error is a preventable event that involves an identifiable patient and that leads to  
inappropriate medication use, which may result in patient harm. While overdoses and 
under doses constitute  medication  errors, doses missed inadvertently by a patient do not. 
 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page [ADDRESS_365776] 
[COMPANY_005] (see below) and report the event. 
 
Produc t compl aints in and of themselves are not  AEs.  If a product compl aint results in an SAE, 
an SAE form should be compl eted and sent to [COMPANY_005] Pharmacovigilance (refer to S ection 8.2).  For Product Complaints or Medication Errors, call 
 
For ADCET RIS or PI[INVESTIGATOR_299701] s: Phone: 1-844-ONC- TKDA ( [PHONE_897]) 
Email: GlobalOncology Med [EMAIL_5907] 
Fax: [PHONE_899], Hours Mon – Fri, 9 a .m. – 7 p.m. ET 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 72 
X31025 Protocol Version  4 24-January- 2020  17. REFE RENCE S 
1. Lopez J, Banerjee S, Kaye SB. New developments in the treatment of ovarian cancer --future 
perspectives. Annals of oncology: official journal of the European Society for Medical Oncology 
/ ESMO. 2013;[ADDRESS_365777] 10:x69- x76. 
2. Despi[INVESTIGATOR_11958] E, Yesilyurt BT, L ambrechts S, et al. Epi[INVESTIGATOR_299702]: rationale for changing 
the one -fits-all standard treatment regimen to subtype -specific treatment. International journal of 
gynecological cancer : official journal of the International Gynecological Cancer Society. 
2014;24:468- 477. 
3. Pene F, Courtine E, Cariou A, Mira JP. Toward theragnostics. Critical care medicine. 
2009;37:S50- 58. 
4. Stewart B. World cancer report 2014: International Agency for Research onCancer,WHO Press, 
World Health Organization; 2014.  
5. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forma n D. Global cancer statistics.  CA: a cancer 
journal for clinicians. 2011;61:69- 90. 
6. Cakir BO, Adamson P, Cingi C. Epi[INVESTIGATOR_299703]. Facial Plast Surg Clin North Am. 2012;20:419- 422. 
7. Dubas LE, Ingraffea A. Nonmelano ma skin cancer. Facial Plast Surg Clin North  Am. 
2013;21:43- 53. 
8. Group USCSW. [LOCATION_002] Cancer Statistics: 1999 –2011 Incidence and Mortality Web- based 
Report. Atlanta, Georgia: U.S. Department of Health and Human Services, Centers for Disease 
Control and Prevention and National Cancer I nstitute; 2014.  
9. Laplante M, Sabatini DM. mTOR Signaling. Cold Spring Harb Perspect Biol. 2012;4.  
10. Laplante M, S abatini D M. mTOR  signaling in growth c ontrol and dis ease. Cell. 2012;149:274-
293. 
11. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nature reviews. Cancer. 
2006;6:729- 734. 
12. Benjamin D, Colombi M, Moroni C, Hall MN. Rapamycin passes the torch: a new generation of 
mTOR inhibitors. Nature reviews. Drug discovery. 2011;10:868- 880. 
13. Vilar E, Perez -Garcia J, Tabernero J. Pushing the envelope in the mTOR pathway:  the second 
generation of inhibitors. Molecular cancer therapeutics. 2011;10:395- 403. 
14. Chresta CM, Davies BR, Hickson I, et al. AZD8055 is a potent, selective, and orally bioavailable 
ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro a nd in vivo 
antitumor activity. Cancer research. 2010;70:288- 298. 
15. Rodrik- Outmezguine VS, Chandarlapaty S, Pagano NC, et al. mTOR kinase inhibition causes 
feedback -dependent biphasic regulation of AKT signaling. Cancer Discov. 2011;1:248- 259. 
16. Thoreen CC, Kang SA, Chang JW, et al. An ATP -competitive mammalian target of rapamycin 
inhibitor reveals rapamycin -resistant functions of mTORC1. The Journal of biological chemistry. 
2009;284:8023- 8032. 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page [ADDRESS_365778] 2240: Pre -clinical potency of IN K128, a highly potent 
TORC1/[ADDRESS_365779] cancer model. Cancer research. 
2012;72:2240. 
18. Hassan B, Akcakanat A, Takafumi S, Evans K, Adkins F, Meric -Bernstam F. MTOR  Inhibitor 
MLN0128 has Antitumor Efficacy in Cell Lines Wit h Intrinsic and Acquired Rapamycin -
Resistance. Journal of Surgical Research.179:313.  
19. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase 
signaling and activates Akt. Cancer research. 2006;66:1500- 1508.  
20. Tabernero J,  Rojo F, Calvo E, et al. Dose - and schedule -dependent inhibition of the mammalian 
target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in 
patients with advanced solid tumors. Journal of clinical oncology : official journal of the 
American Society of Clinical Oncology.  2008;26:1603- 1610.  
21. Jessen K, Wang S, Kessler L, et al. Abstract B148: INK128 is a potent and selective TORC1/[ADDRESS_365780] oral antitumor activity. Molecular cancer therapeutics. 2009;8:B148.  
22. Kessler L, Wang S, Guo X, et al. Abstract 4496: I NK128, an orally active TORC1/[ADDRESS_365781] antitumor activity and enhances efficacy of cytotoxic as well as targeted 
agents. Cancer research. 2010;70:4496.  
23. Brito DA, Rieder CL. Mitotic checkpoint slippage in humans occurs via cyclin B  destruction in 
the presence of an active checkpoint. Curr Biol. 2006;16:1194- 1200.  
24. Shafer A, Z hou C, Gehrig PA, Boggess JF, Bae -Jump VL. Rapamycin potentiates the effects of 
paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of 
apoptosis. International journal of cancer. Journal international du cancer. 2010;126:1144- 1154.  
25. Shu CH, Yang WK, Shih YL, Kuo M L, Huang TS. Cell cycle G2/M arrest and activation of 
cyclin -dependent kinases  associated with low -dose paclitaxel -induced sub- G1 apoptosis. 
Apoptosis. 1997;2:463- 470. 
26. Mondesire WH, Jian W, Z hang H, et al. Targeting mammalian target of rapamycin synergistically 
enhances chemotherapy -induced cytotoxicity in breast cancer cells. Clini cal cancer research : an 
official journal of the American Association for Cancer Research. 2004;10:7031- 7042.  
27. Ollikainen M, Gylling A, Puputti M, et al. Patterns of PIK3CA alterations in familial colorectal 
and endometrial carcinoma. International journal of cancer. Journal international du cancer. 
2007;121:915- 920. 
28. Stemke -Hale K, Gonzalez- Angulo AM, Lluch A, et al. An integrative genomic and proteomic 
analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer research. 
2008;68:6084- 6091. 
29. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene. 
2008;27:5497- 5510. 
30. Spoerke JM, O'Brien C, Huw L, et al. Phosphoinositide 3- kinase (PI3K) pathway alterations are 
associated with histologic subtypes and are predictive of sen sitivity to PI3K inhibitors in lung 
cancer preclinical models. Clinical cancer research : an official journal of the American 
Association for Cancer Research. 2012;18:6771- 6783.  
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 74 
X31025 Protocol Version  4 24-January- 2020  31. Voss M, Gordon MS, Mita M, et al. Phase I  study of investigational oral mTORC1 /2 inhibitor 
MLN0128: Expansion phase in patients with renal, endometrial, or bladder cancer. ESMO poster. 
2015. 
32. Ghobrial IM, Siegel DS, Vij R, et al. TAK- 228 (formerly MLN0128), an investigational oral dual 
TORC1/2 inhibitor: A phase I dose escalation stu dy in  patients with relapsed or refractory 
multiple myeloma, non -Hodgkin lymphoma, or  Waldenstrom's macroglobulinemia. Am J 
Hematol. 2016;91:400- 405. 
33. Zohren F. [COMPANY_005] presents " Inhibiting the mTOR Complex: Biology and Targets" at the 14th 
International Kidney Cancer Symposium. In: Z ohren F, ed. Oncology Tube2015.  
34. Guimarães IS, Tessarollo NG, Lyra- Júnior PCM, et al. Targeting the  PI3K/AKT/mTOR Pathway 
in Cancer Cells: InTech; 2015.  
35. Quintas -Cardama A, Verstovsek S. Molecular pathways: Jak/STAT pathway: mutations, 
inhibitors, and resistance. Clinical cancer research : an official journal of the American 
Association for Cancer Research. 2013;19:1933- 1940.  
36. Van de Bor V, Z imniak G, Cerez o D, Schaub S, Noselli S. Asymmetric localisation of cytokine 
mRNA is essential for JAK/STAT activation during cell invasiveness. Development. 
2011;138:1383- 1393. 
37. Xu R, Nakano K, I wasaki H, et al. Dual blockade of phosphatidylinositol 3' -kinase and mitogen-
activated protein kinase pathways overcomes paclitaxel -resistance in colorectal cancer. Cancer 
Lett. 2011;306:151- 160. 
38. Kim SH, Juhnn YS, Song YS. Akt involvement in paclitaxel chemoresistance of human ovarian 
cancer cells. Ann N Y Acad Sci. 2007;1095:82- 89. 
39. Sun H, Yu T, Li J. Co- administration of perifosine with paclitaxel synergistically induces 
apoptosis in ovarian cancer cells: more than just AKT inhibition. Cancer Lett. 2011;310:118- 128. 
40. Hou H, Z hang Y, Huang Y, et al. I nhibitors of phosphatidylinositol 3' -kinases promote mitotic 
cell death in HeL a cells. PloS one. 2012;7:e35665.  
41. Williams PD, Ducey KA, Sears AM, Williams AR, Tobin -Rumelhart SE, Bunde P.  Treatment 
type and symptom severity among oncology patients by [CONTACT_6270] -report. Int J Nurs Stud. 2001;38: 359-
367. 
42. Williams PD, Williams K, L afaver -Roling S, Johnson R, Williams AR. A n intervention to 
manage patient -reported symptoms during cancer treatment. Clin J Oncol Nurs. 2011;15:253- 258. 
43. Bretscher M, Rummans T, Sloan J, et al. Quality of life in hospi[INVESTIGATOR_69223]. A pi[INVESTIGATOR_799]. 
Psychosomatics. 1999;40:309- 313. 
44. Degner LF, Sloan JA. Symptom distress in newly diagnosed ambulatory cancer patients and as a 
predictor of survival in lung cancer. J Pain Symptom Manage. 1995;10:423- 431. 
45. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: 
revised RECIST guideline (version 1.1). European journal of cancer. 2009;45:228- 247. 
46. Grunberg SM, Groshen S, Steingass S, Z aretsky S, Meyerowitz B. Comparison of conditional 
quality of l ife terminology and visual analogue scale measurements. Qual Life Res. 1996;5:65- 72. 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 75 
X31025 Protocol Version  4 24-January- 2020  47. Hyland ME, Sodergren SC. Development of a new type of global quality of life scale, and 
comparison of performance and preference for 12 global scales. Qual Life Res. 1996; 5:469- 480. 
48. PAC LITAXEL  - paclitaxel injection, solution [pa ckage insert]. Princeton, NJ: Sandoz; 2011.  
49. Abraxane 5 mg/mL powder for suspension for infusion [Summary of Product  Characteristics]. 
Uxbridge, [LOCATION_008]: Celgene Europe Ltd; 2013.  
50. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern 
Cooperative Oncology Group. Am. J. Clin. Oncol. 1982;5:649- 655. 
51. The Criteria Committee of [LOCATION_001] Heart Association. Nomenclature and Criteria for 
Diagnosis of Diseases of the Hear t and Great Vessels. 9 ed. [LOCATION_011], MA: Little, Brown & Co; 
1994. 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 76 
X31025 Protocol Version  4 24-January- 2020  Appendix  1: Eastern Coo perat ive Oncology G roup (ECOG) Scale for Performance Statu s 
 
Grade Description 
0 Normal activity. Fully active, able to ca rry on all predisease performance without restriction 
1 Symptoms but ambulatory. Restricted  in physically strenuous activity, but ambulatory and 
able to ca rry out work of a light or sedentary nature (e.g., light housework, office work) 
2 In bed <50% of the time. Ambulatory and capable of all self-care, but unable to ca rry out any 
work activities. Up a nd about more than 50% of waking hours. 
3 In bed >50% of the time. Capable of only limited self-care, confined to bed or chair more 
than 50% of waking hours. 
4 100% bedridden. Completely disabled. Cannot carry on any self-care. Totally confined to 
bed or chair 
5 Dead  
Source: Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden  ET et al. Toxicity and 
respons e criteria of the Eastern Coope rative Oncology Group. Am J Clin Oncol 1982;  5 (6):649-55.50 
 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 77 
X31025 Protocol Version  4 24-January- 2020  Appendix 2:  Cockcroft-Gault Equ ation 
 
For men:  
 
Creatinine  Clearance = (140-age [years])×weight [kg] 
 72×(serum creatinine  [mg/dL]) 
OR 
Creatinine  Clearance = (140-age [years])×weight [kg] 
 0.81× (serum creatinine  [µmol/L]) 
 
 
For women:  
 
Creatinine  Clearance = 0.85 (140-age [years])×weight [kg] 
 72×(serum creatinine  [mg/dL]) 
OR 
Creatinine  Clearance = 0.85 (140-age [years])×weight [kg] 
 0.81×(serum creatinine [µmol/L])  
 
Source:  Cockcroft DW, Gault MH. Prediction of creatinine  clearance from  serum creatinine. Nephron 
1976;16( 1):31-41 [32]. 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 78 
X31025 Protocol Version  4 24-January- 2020  Appendix 3:  [LOCATION_001] Heart Asso ciation Clas sification of Cardiac Disease 
 
Class Functional Capacity Objective Assessment 
I Patients with cardiac disease but without resulting limitations of No objective evidence of phys ical activity. 
Ordinary phys ical activity does not cause cardiovascular disease. Undue  fatigue, palpi[INVESTIGATOR_332],  dyspn ea, or anginal 
pain. 
II Patients with cardiac disease resulting in slight limitation of Objective evidence of minim al phys ical activity. 
They are comfor table at rest. Ordinary cardiovascular disease. Physical activity resul ts in fatigue, palpi[INVESTIGATOR_332] , 
dyspn ea, or anginal  pain. 
III Patients with cardiac disease resulting in marked limitatio n of Objective evidence of moderately phys ical activity. 
They are comfor table at rest. Less than s evere cardiovascular disease. ordinary activity causes fatigue, 
palpi[INVESTIGATOR_332] , dyspn ea, or angina pain. 
IV Patients with cardiac disease resulting in inability to carry on Objective evidence of severe any physical 
activity without discomfort. Symptoms of heart cardiovascular disease. Failure or the anginal syndrome may 
be present even at rest. If any physical activity is undertaken, discomfort is increased. 
 
• Source:  The Criteria Committe e of [LOCATION_001] Heart Asso ciation. Nom enclature and 
Criteria for Diagnosis of Dis eases of the Heart and Great Vessels. Ninth  Ed. [LOCATION_011], MA:  
Little, Brown &  Co; 1994:253- 256.51 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 79 
X31025 Protocol Version  4 24-January- 2020  Appendix 4:  List of Relevant Cytochrome P450 Inhibitors and Inducers  
 
Strong CYP2 C19 Inhibi tors 
fluconazole  
 
fluvoxamine  
 
ticlopi [INVESTIGATOR_299704]3 A4 Inhibi tors   
amprenavir darunavir/ritonavir fosamprenavir 
aprepi[INVESTIGATOR_299705] (a) 
ataza navir erythromycin imatinib 
ciprofloxacin fluconazole verapamil 
Strong CYP3 A4 Inhibi tors   
boceprevir ketoconazole ritonavir 
clarithromycin lopi[INVESTIGATOR_054]/ritonavir saquinavir 
conivaptan mibefradil (b) telaprevir 
grapefruit juice (a) nefazodone telithromycin 
indinavir nelfinavir voriconazole 
itraconazole posaconazole  
Clinic ally Significant Enzyme Induce rs 
carbamazepi[INVESTIGATOR_299706]. Johns Wort 
phenobarbital rifampin  
phenytoin rifapentine  
 
Source: fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractio nsLabeling/ucm093664. htm. 
 
Note that these lists are not exhaustive. 
(a) The effect of grapefruit juice varies widely among brands and is concentration-, dose-, and preparation- dependent. 
Studies have shown that it can be classified as a “strong CYP3A inhibitor” when a certain preparation was used (e.g., 
high dose, double strength) or as a “moderate CYP3A inhibitor” when another preparation was used (e.g., low dose, 
single strength). 
 (b) Withdrawn from the [LOCATION_002]  market becaus e of safety reasons. 
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 80 
X31025 Protocol Version  4 24-January- 2020  Appendix  5: Guidelines for TAK -228/TAK -117 and Paclitaxel Dose Modification and Delay  
 
Table Guidelines for TAK -228/TAK -117 and Paclitaxel Dose Modification and Delay (after 
cycle 1 only)  
Please refer to MLN0128 dose changes in the following tables to include both TAK -228 and TAK -117.  
 
 

PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 81 
X31025 Protocol Version  4 24-January- 2020  Table Guidelines for TAK -228/TAK -117 and Paclitaxel Dose Modification and Delay  
  
 
 

PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 82 
X31025 Protocol Version  4 24-January- 2020  Table Guidelines for TAK -228/TAK -117 and Paclitaxel Dose Modification and Delay (> cycle 1)  
 
 
 
 
 
 
>[ADDRESS_365782] ) 
Please refer to recommended labs, listed under Grade 2 . This is  per investigator’s discretion.  

PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 83 
X31025 Protocol Version  4 24-January- 2020   
 APPENDIX 6: HEALTH RELATED QU ALITY OF LIFE  
HEALTH -RELATED QUALITY OF L IFE (HRQOL), LINEAR ANALOGUE SELF 
ASSESSMENT (LASA)  
Patient Name: ____________ ___________________ Date: ______________________ 
Patient Number:  ______________________________  
 
Directions: Please circle the number (0 -10) best reflecting your response to the following 
that describes your feelings during the past week, including today . 
How would you describe:  
 
1. your overall Quality of Life?   
 0 1 2 3 4 5 6 7 8 9 10   
 As bad as          As good as  
 it can be           it can be   
2. your overall mental (intellectual) well being?   
 0 1 2 3 4 5 6 7 8 9 10   
 As bad as          As good as  
 it can be           it can be   
3. your overall physical well being?  
 0 1 2 3 4 5 6 7 8 9 10   
 As bad as          As good as  
 it can be           it can be   
4. your overall emotional well being?  
 0 1 2 3 4 5 6 7 8 9 10   
 As bad as          As good as  
 it can be           it can be   
5. your level of social activity?   
 0 1 2 3 4 5 6 7 8 9 10   
 As bad as          As good as  
 it can be           it can be   
6. your overall spi[INVESTIGATOR_280047]?   
 0 1 2 3 4 5 6 7 8 9 10   
 As bad as          As good as  
 it can be  it can be  
 
 
 
  
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 84 
X31025 Protocol Version  4 24-January- 2020   
APPENDIX 7: THERAPY RELATED S YMPTOMS CHECKLIST  
THERAPY- RELATED SYMPTOMS CHECKLIST ( TRSC)  
Name:                                                              [CONTACT_23189][INVESTIGATOR_307] #                    Date:             
  
PLEASE  CHECK  THE  PROBLEMS  YOU  HAVE  HAD  IMMEDIATELY  AFTER  AND  SINCE  
YOUR   LAST  TREATMENT.    PLEASE  CIRCLE   HOW  SEVERE  THE  PROBLEM  WAS 
ACCORDING TO THE FOLLOWING SCALE:  
  
0 = NON E          1 = MILD         2 = MODERATE         3 = SEVERE             4 = VERY SEVERE  
 CHECK   
  EXAMPLE   
Pain  Degree of Severity (CIRCLE)   
0  1  2    4  
  Taste Change  0  1  2  3  4  
  Loss of appetite  0  1  2  3  4  
  Nausea  0  1  2  3  4  
  Vomiting  0  1  2  3  4  
  Weight loss  0  1  2  3  4  
  Sore mouth  0  1  2  3  4  
  Cough  0  1  2  3  4  
  Sore throat  0  1  2  3  4  
  Difficulty swallowing  0  1  2  3  4  
  Jaw pain  0  1  2  3  4  
  Shortness of breath  0  1  2  3  4  
  Numbness in fingers and/or toes  0  1  2  3  4  
  Feeling sluggish  0  1  2  3  4  
  Depressio n  0  1  2  3  4  
  Difficulty concentrating  0  1  2  3  4  
  Fever  0  1  2  3  4  
  Bruising  0  1  2  3  4  
  Bleeding  0  1  2  3  4  
  Hair loss  0  1  2  3  4  
  Skin changes  0  1  2  3  4  
  Soreness   in   vein   where   chemotherapy  
was given  0  1  2  3  4  
  Difficulty sleepi[INVESTIGATOR_007]  0  1  2  3  4  
  Pain  0  1  2  3  4  
  Decreased interest in sexual activity  0  1  2  3  4  
  Constipation  0  1  2  3  4  
  Other problems (please list below)            
   
                                   0  1  2  3  4  
   
                                   0  1  2  3  4  
   
                                   0  1  2  3  4  
   
                                   0  1  2  3  4  
PI[INVESTIGATOR_299658] (TAK -228 + TAK -117) 
Clinical Study Protocol X31025  
Confidential  Page 85 
X31025 Protocol Version  4 24-January- 2020  Phoebe D. Williams, PhD ©Copyright 1995 University of Kansas Medical Center  